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1. Summary 
 
RNA-protein interactions play a key role in fundamental cellular processes in 
living organisms. As this type of interaction is a common regulator in 
pathogenic networks, it is of special interest to be investigated. A number of in 
vitro methods have been established to isolate RNA binding proteins. 
However, these in vitro approaches may result in artificial interactions that 
would not occur within cellular conditions. Here, the “StreptoTag” method for 
isolation of RNA binding proteins in vivo is presented. The StreptoTag 
method, a novel technique to identify RNA-protein interactions, employs in 
vitro transcribed RNA target sequences, which are tagged with an RNA 
aptamer (STag) specifically binding to streptomycin. RNA binding proteins 
from crude cell extracts may bind to the chromatographically immobilised 
target RNA and are then co-eluted by addition of streptomycin. In the 
presented work, the system was adapted for in vivo applications. Therefore, 
putative protein target STag-RNA was transiently expressed in eukaryotic 
cells, allowing RNA-protein interactions to occur under physiological 
conditions. For a proof-of-principle, we isolated the human immunodeficiency 
virus-1 (HIV-1) RNA binding protein Rev from HEK293 cells by expressing 
STag-RNA harbouring the Rev responsive element (RRE). Standardisation of 
the method included high-level target RNA synthesis in transfected cells and  
optimisation of binding conditions, allowing high affinity interaction of Rev with 
the STag-RRE-RNA. In the final step, target RNA and Rev protein were co-
expressed in HEK293 cells and successfully purified by affinity 
chromatography. In conclusion, the established in vivo StreptoTag method 
may facilitate isolation and identification of currently unknown RNA binding 
proteins and further protein interacting factors in cellular environments. 
                                                                                             Zusammenfassung 
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2. Zusammenfassung 
 
RNA-Protein Interaktionen spielen eine Schlüsselrolle in fundamentalen 
zellulären Prozessen aller lebenden Organismen. Diese Art der Interaktion ist 
vor allem in pathogenen Netzwerken involviert und folglich von besonderem 
Interesse. Eine Vielzahl in vitro basierender Methoden für die Isolierung RNA 
bindender Proteine wurde etabliert, wobei diese jedoch oftmals zur Isolierung 
von Artefakten führen, welche unter zellulären Bedingungen nicht anzutreffen 
wären. Die hier vorgestellte neuartige Methode ist eine Technik zur 
Identifizierung von RNA-Protein Interaktionen basierend auf einem in vitro 
transkribierten RNA Aptamer (STag) und dessen spezifischer Bindung an 
Streptomycin. RNA-bindende Proteine aus rohem Zellextrakt binden im 
Folgenden an die chromatographisch immobilisierte Ziel-RNA und können 
durch Zugabe von Streptomycin co-eluiert werden. In der vorliegenden Arbeit 
wurde dieses System für eine Anwendung in vivo angepasst. Hierzu wurden 
eine STag-RNA mit einer Protein-bindenden Sequenz transient in 
eukaryonten Zellen exprimiert, und damit die RNA-Protein Interaktion unter 
zellulären Bedingungen ermöglicht. Zum Nachweis, dass dieses Prinzip 
grundsätzlich funktioniert, wurde das HIV-1 RNA-bindende Protein Rev aus 
HEK293 transfizierten Zellen isoliert. Für die Standardisierung der Methode 
war ein hohes Syntheselevel der Ziel RNA in transfizierten Zellen sowie die 
Optimierung der Bindungskonditionen von Rev zur SRS-RNA 
ausschlaggebend. Im finalen Schritt wurden HEK293 Zellen mit dem RNA- 
sowie dem Protein-kodierenden Vektor co-transfiziert und das Rev Protein 
erfolgreich durch Affinitätschromatographie aufgereinigt. Die hiermit etablierte 
in vivo StreptoTag Methode sollte zukünftig die Isolierung sowie 
Identifizierung von bislang unbekannten RNA-bindenden Proteinen sowie 
Protein-interagierenden Faktoren in zellulärem Umfeld erleichtern. 
                                                                                                         Introduction 
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3. Introduction 
 
3.1 RNA - protein interactions 
 
RNA-protein interactions play a key role in fundamental processes of all living 
organisms. For example, interaction of the Epstein-Barr virus (EBV)-encoded 
RNA EBER-1 and the host cellular ribosomal protein L22 correlates with 
growth-promoting properties (Houmani, Davis et al. 2009). Similarly, the 
breast cancer susceptibility gene BRCA1 is posttranscriptionally regulated by 
the RNA binding protein HuR (Saunus, French et al. 2008). Furthermore, 
RNA-protein interactions are of central importance in host-pathogen 
interactions as for example in human immunodeficiency virus (HIV)-1, where 
multiple RNA-interacting proteins mediate reverse transcription of RNA and 
integration of cDNA into the host genome. So far, mainly in vitro methods 
were available for identifiction of RNA-protein interactions, e.g., those which 
are based on the interaction of biotin with streptavidin. This method implies 
biotinylation of target RNAs which are subsequently immobilised on 
streptavidin-coupled sepharose or magnetic beads. Cell extracts are mixed 
with these beads and target proteins interacting with the biotinylated RNA are 
retained upon elution. As this method is based on posttranscriptional 
modification of RNA in vitro, non-physiological conditions may contribute to 
formation of protein-RNA interactions that would not have occured under 
physiological conditions within the cell. Moreover, since the secondary and 
tertiary structure of the target RNA determines successful protein binding 
(Zhang, Jun Cho et al. 2010), posttranslational modification such as 
biotinylation might impair RNA structure and therefore contribute to a 
decreased specificity of such in vitro based assays. Previously, the 
StreptoTag method, a new chromatography-based purification technique for 
RNA-binding proteins, has been developed (Bachler, Schroeder et al. 1999) 
and was further improved by alteration of the StreptoTag RNA aptamer to 
increase specificity (Dangerfield, Windbichler et al. 2006). 
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3.2 The StreptoTag method 
 
3.2.1 The basics of streptomycin-RNA interaction 
 
Streptomycin is a member of the aminoglycoside antibiotics. Its specific 
interaction with RNA was identified by interfering with ribosomal subunits. The 
antibiotic has been shown to suppress missense and nonsense codons in 
vivo, and to induce misreading of the genetic code in vitro (Davies, Gilbert et 
al. 1964; Pestka, Marshall et al. 1965; Garvin, Biswas et al. 1974). Specific 
interaction of streptomycin with ribosomal RNA was shown by chemical 
modification assays performed with ribosomes bound to streptomycin 
(Moazed and Noller 1987). Furthermore, streptomycin was found to interact 
with, and thus inhibit self-splicing of group I intron RNA (von Ahsen and 
Schroeder 1991). In vitro selection, applying affinity chromatography and 
chemical probing, using dimethylsulfate and kethoxal, revealed streptomycin-
binding RNA aptamers and defined secondary structures. The minimal size of 
an aptamer required to bind to streptomycin was determined to be a 46-mer 
RNA (see Figure 3.2.1.1). The presence of Mg2+ was found to be a 
prerequisite to facilitate binding of streptomycin to RNA (Wallace and 
Schroeder 1998). 
 
Figure 3.2.1.1 Streptomycin-binding RNA aptamer. A 46-mer RNA aptamer was 
determined to be the prerequisite for streptomycin binding to RNA (virtual folding carried out 
using the “mfold” webserver; Zuker, 2003). 
                                                                                                         Introduction 
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3.2.2 The StreptoTag method and its modifications 
 
For further application, i.e. the isolation of RNA-binding proteins, the 
streptomycin-binding RNA aptamer (StreptoTag) was expressed as a hybrid 
RNA fused to the putative protein binding RNA sequence of interest (Figure 
3.2.2.1). The Strepto-tagged hybrid RNA was then loaded onto a 
dihydrostreptomycin-coupled sepharose column; the subsequently applied 
RNA-binding protein is retained on the column and eluted upon addition of 
streptomycin (Bachler, Schroeder et al. 1999), Figure 3.2.2.2). In order to 
increase affinity and specificity of the StreptoTag aptamer, the original 
AGGGU apex of the hairpin, nucleotides 24 to 28,  was modified to form a 
GCAAG loop (Figure 3.2.2.3), resulting in enhanced stability and increased 
binding efficacy to streptomycin from 65.3 % to 81.3 % (Dangerfield, 
Windbichler et al. 2006). Furthermore, larger RNA molecules of up to at least 
550 nt were capable to efficiently bind to the streptomycin-coupled column 
material, thus making this enhanced GCAAG aptamer the tag of choice for the 
work presented hereafter. 
 
 
 
Figure 3.2.2.1 Hybrid Strepto-tagged target RNA. The streptomycin-binding RNA aptamer 
(StreptoTag) is linked to the putative protein binding RNA (RNA X) at the 5’ end and 
expressed as a hybrid (Bachler, Schroeder et al. 1999). 
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Figure 3.2.2.2 Schematic drawing of the StreptoTag-based affinity purification. A) The 
sepharose column material is coupled with dihydrostreptomycin. B) RNA-binding proteins are 
directly applied to the column. C) The RNA-bound protein is retained on the column due to 
the interaction of the StreptoTag and the streptomycin-coupled sepharose. Unspecific cellular 
proteins are removed in 4-5 consecutive washing steps. D) The RNA-bound protein of 
interest is eluted upon addition of streptomycin, separated by gel electrophoresis and 
detected using Western blotting or silver staining and mass spectrometrical analysis.  
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Figure 3.2.2.3 Altered streptomycin-binding RNA aptamer. Modification of the nucleotides 
24 to 28 of the apex of the StreptoTag hairpin from AGGGU to a GCAAG tetraloop resulted in 
increased stability and binding efficiency (Dangerfield, Windbichler et al. 2006); virtual folding 
carried out using the “mfold” webserver; Zuker, 2003). 
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3.3 Viral RNA-protein interactions 
 
3.3.1 HIV-1 regulator of virion expression (Rev) and Rev responsive element 
(RRE) 
 
For establishment of the StreptoTag method-based affinity purification of 
proteins in vivo, a well investigated system was chosen. Therefore, the well 
known (Freed 2001) RNA-protein interaction of the HIV-1 regulator of virion 
expression (Rev) protein and the Rev responsive element (RRE) RNA was 
used as a model. The HI-virus is an RNA retrovirus with a complex gene 
regulation.  
 
 
Figure 3.3.1.1 Retroviral replication cycle. Following binding and fusion of the viral particle, 
retroviral RNA is reversely transcribed into cDNA and integrated into the host genome. Viral 
RNAs are transcribed from provirus DNA and translated into viral proteins, which assemble in 
the cytoplasm to form a new functional retrovirus (adapted from Nisole, Stoye et al. 2005)). 
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In the retroviral life cycle (Figure 3.3.1.1), after fusion with the host cell, viral 
RNA is reversely transcribed into cDNA. The cDNA is subsequently integrated 
into the host genome. Utilizing the hosts transcription and translation 
machinery, provirus DNA is transcribed and spliced as well as mRNAs 
translated into the regulatory proteins Tat, Nev and Rev. On the other hand, 
the Rev protein binds to unspliced viral RNAs carrying the RRE, such as 
RNAs encoding the Gag, Pol, Env, Vif and Vpr proteins, thereby mediating 
their export from the nucleus to the cytoplasm. The viral proteins assemble in 
the cytoplasm and a new functional viral particle is budding from the cellular 
surface, (Figure 3.3.1.1, adapted from Nisole, Stoye et al. 2005). 
 
 
 
Figure 3.3.1.2 HIV-1 provirus DNA and splicing of full length RNA into subgenomic 
mRNA. LTR, Long terminal repeats; U3, Unique region 3; R, Repeat region; U5, Unique 
Region 5; SD, Splice Donor; SA, Splice Acceptor; RRE, Rev responsive element; gag, group-
specific antigen; pol, reverse transcriptase, integrase, protease; vif, viral infectivity factor; 
vpr, viral protein R; vpu, viral protein U; env, envelope; nef, negative regulatory factor; 
 
Transcription initiating at the HIV-1 5’ LTR generates a large number of viral 
RNAs. These are classified in 1) unspliced RNAs, which function as mRNAs 
for the Gag and GagPol polyprotein precursors, 2) partially spliced mRNAs, 
which encode the Env, Vif, Vpu and Vpr proteins and 3) multiply spliced 
mRNAs, which are translated into Rev, Tat, and Nef (Purcell and Martin 1993,  
Figure 3.3.1.2). As most cellular mRNAs are transported out of the nucleus 
fully spliced, the need for unspliced and partially spliced RNAs in the 
cytoplasm poses a problem for HIV. This has been overcome through the 
evolution of the viral protein Rev (Regulator of virion expression) and a cis-
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acting RNA element, the RRE (Rev responsive element), carried by those 
unspliced and partially spliced RNAs to be exported (Figure 3.3.1.3).  
 
 
 
Figure 3.3.1.3 Export of mRNA in HIV-1. HIV-1 export of spliced RNA and Rev-dependent 
export of unspliced and partially spliced RNA in the late phase of the viral replication cycle. I, 
intron. 
 
Rev is a 13 kDa phosphoprotein composed of 116 amino acids which are 
encoded by two exons, both of which are essential for protein function 
(Pollard and Malim 1998). The determined molecular weight of Rev protein is 
17 kDa, consistent with other proteins rich in basic amino acid residues (Nalin, 
Purcell et al. 1990). Rev contains two functional domains: an arginin-rich 
sequence required for RNA binding and nuclear localisation, and a 
hydrophobic leucine-rich motif that mediates nuclear export. The 250 nt long 
Rev responsive element (RRE) is located in the env gene and is present in all 
unspliced and partially spliced HIV-1 RNAs (Freed 2001). The HIV-1 Rev 
protein multimerises into eight molecules by binding to the RRE, thereby 
forming a complex capable of interacting with the cellular nuclear export 
machinery. Consequently, the RRE-containing unspliced or partially spliced 
RNA is transported to the cytoplasm. Rev then shuttles back to the nucleus, 
using its nuclear localisation signal (NLS) (Rosen, Terwilliger et al. 1988; 
Maldarelli, Martin et al. 1991; Figure 3.3.1.3). 
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3.3.2 MMTV regulator of export of MMTV mRNA (Rem) and Rem responsive 
element (RmRE) 
 
Similarly to the well established HIV-1 Rev/RRE RNA-transport system, an 
equivalent but less investigated interaction has been recently described for 
the mouse mammary tumor virus (MMTV). This virus belongs to the family of 
complex retroviruses. It encodes regulatory as well as accessory proteins 
such as a superantigen (Sag) (Acha-Orbea and Palmer 1991; Marrack, 
Kushnir et al. 1991), a negative-acting factor (Naf) (Salmons, Erfle et al. 1990) 
and a regulator of export of MMTV mRNA (Rem), (Indik, Günzburg et al. 
2005). Analogue to the HIV-1 Rev protein, the MMTV Rem is required for 
nuclear export of unspliced viral RNA, which is carrying the Rem responsive 
element (RmRE). The RmRE is a 490 nt long region that spans the env-3’LTR 
junction (Müllner, Salmons et al. 2008; Figure 3.3.2.1). 
 
 
 
Figure 3.3.2.1 MMTV mRNA splicing and generation of Rem p14 by cleavage of full 
length Rem (adapted from Byun, Halani et al. 2010). LTR, Long terminal repeats; U3, Unique 
region 3; R, Repeat region; U5, Unique Region 5; SD, Splice Donor; SA, Splice Acceptor; 
RmRE, Rem responsive element; NoLS, Nucleolar localisation sequence; NES, Nuclear 
export sequence; NLS, Nuclear localisation sequence. 
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The MMTV Rem protein has a calculated molecular weight of 34 kDa and is a 
product of the doubly spliced 906 nt long pre-mRNA transcript. Due to two 
potential asparagine-linked glycosylation sites, which in case of glycosylation 
increase the molecular weight by 2.5 kDa each, the actually observed 
molecular weight of Rem is 39 kDa. The protein contains a highly basic 
arginine-rich N-terminal region which resembles a NLS (nuclear localisation 
signal) and confers to RNA binding abilities as well as to nuclear localisation 
of the protein. A leucine-rich domain, which in HIV-1 Rev is referred to as the 
NES (nuclear export signal), is also present in MMTV Rem. For nuclear 
function, Rem protein requires proteolytic processing by a signal peptidase at 
the endoplasmic reticulum. Subsequent, the Rem(p14) signal peptide re-
translocates into the nucleus to mediate export of unspliced viral RNA (Figure 
3.3.2.2).  
 
 
Figure 3.3.2.2 Export of mRNA in MMTV infected cells. MMTV export of spliced RNA and 
Rem-dependent export of unspliced RNA in the late phase of the viral replication. The nuclear 
export of single-spliced env mRNA is accomplished via a yet unknown distinct, Rem- 
independent export mechanism (Müllner, Salmons et al. 2008). Full-length MMTV Rem 
undergoes proteolytic cleavage in the ER (endoplasmic reticulum) resulting in gp32Rem and 
Rem(p14) which is transported back into the nucleus. I, intron. 
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Since unspliced RNA is essential but its export is prevented in the retroviral 
life-cycle, retroviruses evolved mechanisms to circumvent the cellular splicing 
machinery. In MMTV infected cells the export of unspliced viral RNA is 
accomplished by the Rem/RmRE system. The presence of the NLS and NES 
consensus sequences suggests that MMTV Rem shuttles between the 
nucleus and the cytoplasm (Indik, Günzburg et al. 2005), thereby exporting 
RRE-carrying unspliced viral RNA from the nucleus into the cytoplasm. As 
HIV-1 Rev, also MMTV Rem protein multimerises during binding to the RmRE 
to become functionally active (Mertz, Lozano et al. 2009). The 490 nt long 
RmRE spans the Env-LTR junction region and its presence is mandatory for 
the Rem-dependent export of the unspliced viral RNA encoding the proteins 
Pol, Pro, and Env. In contrast, single spliced env mRNA is exported from the 
nucleus via a yet unknown, distinct, Rem-independent export mechanism 
(Müllner, Salmons et al. 2008). 
 
3.3.3 StreptoTag-mediated Rev-RRE binding in vitro 
 
For establishment of the StreptoTag method in vivo, a stepwise approach was 
chosen in order to avoid complications and allow modifications and 
optimization of each single step. The work presented hereafter, is a 
continuous follow up of previous achievements such as enhancement of the 
StreptoTag RNA aptamer (Dangerfield, Windbichler et al. 2006). Recent 
approaches (Müllner Matthias, Diploma Thesis 2007) have shown binding of 
Strepto-tagged RNA to dihydrostreptomycin-coupled sepharose columns as 
well as an increase in binding affinity of a double Strepto-tagged RNA 
aptamer in comparison to the use of a single StreptoTag. Finally, 
recombinantly expressed HIV-1 Rev was purified using in vitro transcribed 
double Strepto-tagged HIV-1 RRE RNA (SRS) (Müllner Matthias, Diploma 
Thesis 2007). Based on these findings, the present study should start by 
reproducing StreptoTag-mediated affinity purification of recombinantly 
produced HIV-1 Rev protein and in vitro transcribed SRS-RNA. 
Thereafter, in two different steps, in vitro components should be substituted to 
allow investigation of RNA-protein interaction in an in vivo setting. The system 
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should be established based on the well-known interaction of HIV-1 Rev and 
its responsive RNA element, the RRE. 
 
3.3.4 Aim of this project 
 
The aim of this project was to adapt and establish the StreptoTag method for 
application under physiological conditions. Therefore, a stepwise approach 
from affinity purification of in vitro transcribed RNA and FPLC-purified 
recombinant protein towards a purification of protein-RNA complexes from co-
transfected cells was chosen. The stepwise approach was designed as 
follows : 
 
1. Affinity purification using in vitro transcribed double Strepto-tagged 
HIV-1 RRE (SRS) and FPLC-purified recombinant HIV-1 Rev 
2. Affinity purification of cellular HIV-1 Rev using in vitro transcribed SRS-
RNA 
3. Affinity purification of cellular HIV-1 Rev directly from HEK293 cells co-
transfected with the SRS and Rev encoding vector. 
 
Within the first step in establishment of the method it should be determined if 
double Strepto-tagged RRE is able to bind to and be retained by the 
dihydrostreptomycin-coupled sepharose column and allows recognition and 
binding to the secondary structure by Rev. Second, it should be investigated if 
the purified recombinant HIV-1 Rev is functional and thus able to bind to its 
responsive element in order to be purified. 
After successful isolation of recombinant HIV-1 Rev using in vitro transcribed 
SRS-RNA, the second step should be to isolate the protein directly out of 
HEK293 cells transiently transfected with the HIV-1 Rev encoding vector. As 
this is supposed to be an intermediate step, still in vitro transcribed SRS-RNA 
should be used for affinity purification of cellular Rev. A successful detection 
of cellular HIV-1 Rev either by Western blot or silver staining will be pre-
requisite to proceed, as sufficient amounts of protein have to be produced for 
proper detection. Furthermore, in advance to the final step, the cellular 
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expression level of SRS-RNA should be determined to ensure that the 
minimum level of SRS-RNA, which is required for the successful isolation of 
HIV-1 Rev in the first step, is transcribed. 
In the final step, the StreptoTag method should be applied in a completely 
physiological environment. Therefore, HEK293 cells will be transiently co-
transfected with the HIV-1 Rev as well as the SRS encoding vector allowing 
the RNA-protein interaction to occur under cellular conditions. Cell lysates will 
be prepared without disrupting protein interactions and directly applied to the 
column. Transiently expressed cellular HIV-1 Rev bound to in vivo transcribed 
SRS-RNA should be retained on the column due to the affinity of the 
StreptoTag to the dihydrostreptomycin-coupled sepharose column. Upon 
elution and separation in an agarose gel, the protein should be detectable 
either by Western blotting or silver stain. 
                                                                                        Materials and Methods 
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4. Materials and Methods 
 
4.1 Recombinant DNA technology 
 
4.1.1 Virtual cloning 
 
Cloning of plasmid DNA, restriction endonuclease digests as well as design of 
DNA oligonucleotide primers for polymerase chain reaction (PCR) were 
planned using the Clone Manager 5 from Sci-Ed software. Using Clone 
Manager 5 it was possible to predict sizes of cloning products, annealing 
temperatures of primers applied in PCR (see materials and methods 4.7), 
sizes of PCR products as well as calculating DNA fragment sizes resulting 
from restriction endonuclease digests (see materials and methods 4.1.2) in 
fully annotated plasmid maps. 
 
4.1.2 Restriction endonuclease digests 
 
Each restriction endonuclease digest was simulated before, using the 
software Clone Manager 5 (see materials and methods 4.1.1). The program 
generated a list of all DNA fragments that should be obtained by 
electrophoretical separation. 
All restriction enzymes were purchased from Promega and used with the 
included corresponding buffer as well as bovine serum albumine (BSA). When 
performing a double digest, the most suitable buffer for both enzymes was 
chosen as recommended by the manufacturer. Restriction endonuclease 
digests were performed in 1.5 ml polypropylene tubes (Eppendorf) in a 
volume of 20 µl with a maximum of 1 µg DNA per 10 units of enzyme. 
After components were mixed properly by pipetting, the mixture was incubated 
at 37°C for 1 hour. For preparative digests, the amounts were scaled up 
linearly to a maximum of 500 µl reaction volume.  
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Reaction mixture for a standard analytical digest :  
 
1 µg plasmid DNA 
2 µl 10x buffer 
2 µl BSA (1 µg/µl) 
1 µl restriction enzyme (10 u/µl)                    
ddH2O up to 20 µl 
 
4.1.3 Agarose gel electrophoresis 
 
Agarose gel electrophoresis is the standard method to separate DNA 
fragments by size. By applying an electric current, negatively charged nucleic 
acids migrate through the agarose gel to the cathode in a gel of a percentage 
of 0.5%-2%, corresponding to the expected size of the fragment to be 
analysed. Smaller fragments are less retained in movement and therefore 
migrate faster than larger ones. Gels were prepared by mixing agarose 
(Invitrogen) in 1 x TAE buffer and followed by cooking in a microwave oven at 
750 W until the agarose was dissolved completely. The gel was left on the 
magnetic stirrer for 10 min to cool down below 50°C and warm agar was 
poured into the prepared gel chamber holding a comb (PEQLab 
Biotechnology). After 25 min, the gel was cured and the chamber filled with 1 x 
TAE buffer. Samples with 5 x  loading buffer were loaded into the slots and 
separated by application of an electric current of 90 V and 500 mA for 1-2 
hours, depending on the size of the fragments. Following separation, the gel 
was stained in a 1 x TAE buffer containing 0.5 µg/ml ethidium bromide 
(Sigma). Ethidium bromide is absorbed by the gel, incorporates into DNA and 
shows fluorescence upon exposure to UV-light of 254 nm in wave length, 
making separated DNA fragments visible. For documentation, the gel was 
photographed using the UV Vilber-Lourmat gel documentation system. 
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50xTAE buffer :     2 M  Tris base  
 7.51% Acetic acid (v/v) 
 50 mM Ethylenediaminetetraacetic acid (EDTA) 
 pH 8.0 
 
5xLoading buffer : 0.25% Bromphenol blue 
 0.25% Xylene cyanol 
 0.25% Orange G 
 30% Glycerol 
 10 mM  EDTA 
 in ddH2O 
 
4.1.4 Purification of DNA fragments from agarose gels 
 
For further processing, the DNA fragment of interest was excised using a 
clean scalpel under UV-light (UV-lamp Vilber-Lourmat) with the lowest 
intensity possible to avoid radiation-induced damage of DNA. For DNA 
purification, the Wizard SV Gel and PCR Clean-Up System from Promega was 
used. According to the protocol, membrane binding solution at a ratio of 10 µl 
per 10 mg of agarose gel slice was added to a 1.5 ml polypropylene tube and 
incubated at 65°C in a heating block until the agarose was dissolved 
completely. Next, the mixture was transferred to the SV minicolumn and 
incubated 1 min at room temperature following centrifugation at 16000 x g for 
1 min (Eppendorf table top centrifuge). The flow-through was discarded and 
the column washed by adding 700 µl wash solution and centrifugation at 
16000 x g for 1 min. Again the flow-through was discarded and the washing 
step repeated with 500 µl of membrane wash solution and centrifugation at 
16000 x g for 5 min. The collection tube was emptied and centrifuged for 1 min 
with the lid open to allow evaporation of residual ethanol. The SV minicolumn 
was placed in a clean 1.5 ml polypropylene tube and to elute DNA bound to 
the resin, 50 µl of ddH2O were added, incubated for 1 min at room 
temperature and then spun down for 1 min at 16000 x g. The concentration of 
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purified DNA was determined (see materials and methods 4.1.5) and either 
stored at -20°C or directly used. 
 
4.1.5 Determination of nucleic acid concentrations 
 
DNA as well as RNA concentration measurements were performed with a 
spectrophotometer GeneQuantPro from GE Healthcare. Therefore, samples 
were diluted 1 : 40 and then exposed to UV-light of 260 nm wavelength. The 
more nucleic acids the solution contained, the higher the absorption of UV-
light and the resulting concentration calculated. The DNA to protein ratio 
measured at 260 nm and 280 nm, respectively, should range from 1.6 to 1.9, 
indicating limited protein contamination.  
 
4.1.6 Processing of 5’ and 3’ DNA ends 
 
In order to produce recombinant plasmid DNA, different fragments either with 
blunt or sticky ends need to be joined. Therefore it is necessary to process the 
3’ and 5’ ends, respectively, in order to proceed. If the ends of DNA fragments 
were cut with different restriction enzymes and are incompatible, a blunt end 
ligation is considered. To generate blunt ends, T4 DNA polymerase was used 
for removing 3’ overhangs mediated by its 3’ - 5’ exonuclease activity, and 
filling 5’ overhangs mediated by 3’ - 5’ polymerase activity. To avoid intra-
molecular self-ligation of DNA fragments, terminal phosphate groups were 
removed by dephosphorylation using alkaline phosphatase derived from calf 
intestine (CIAP - Promega). 
 
T4 DNA polymerase mixture : 20 µl  5 x T4 DNA polymerase buffer 
 20 µl  0.5 mM dNTP mix (Promega) 
 0.5 - 0.25 µg DNA 
 2 µl  T4 DNA polymerase (5 U/µl) 
 in ddH2O up to 100 µl final volume 
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The reagents were mixed by pipetting  followed by incubation at 11°C for 15 
min. Subsequently the DNA was purified using the Wizard SV Gel and PCR 
Clean-Up System (see materials and methods 4.1.4). 
 
Dephosphorylation : 5 µl  10 x dephosphorylation buffer 
 1 µl CIAP enzyme (0.1 U/µl) 
 1 – 25 µg DNA 
 in ddH2O up to 50 µl final volume 
 
After proper mixing, incubation followed at 37°C. After 30 min an additional 1 
µl of CIAP was added and incubated for further 30 min. CIAP was inactivated 
by incubation at 56°C for 30 min. Dephosphorylated DNA was purified using 
the Wizard SV Gel and PCR Clean-Up System (see materials and methods 
4.1.4). 
 
4.1.7 DNA Ligation 
 
To join either sticky or blunt ended DNA fragments, T4 DNA ligase was used 
to catalyse formation of phosphodiester bonds between the 5’ phosphate end 
of one and the 3’ hydroxyl end of another nucleotide. The vector and insert 
fragments were ligated at a molar ratio of 1 : 3, with concentrations determined 
by a spectrophotometer (see materials and methods 4.1.5). 
 
Conditions for sticky ends : 4 µl   5 x ligase reaction buffer 
 0.01-0.1 µg  total DNA 
 0.1 unit  T4 DNA ligase                 
 in ddH2O up to 20 µl final volume 
 23°C  incubation temperature 
 1 h   incubation time 
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Conditions for blunt ends : 4 µl   5 x ligase reaction buffer 
 0.1-1 µg   total DNA 
 1 unit  T4 DNA ligase 
 in ddH2O up to 20 µl final volume 
 14°C  incubation temperature 
 16-24 h   incubation time 
 
Following ligation, DNA was precipitated with butanol to minimize salt 
concentrations that might impair efficiency of subsequent bacterial 
transformations. Therefore the reaction volume was increased to 50 µl with 
ddH2O and 500 µl of 1-butanol were added. After vortexing for 30 sec, the 
precipitate was spun down by centrifugation for 30 min. at 16000 x g. 
Supernatant was discarded carefully and the DNA containing pellet dried in an 
Eppendorf Speed-Vac vacuum dryer followed by resuspension in 20 µl of 
ddH2O.  
 
4.1.8 Transformation of plasmid DNA into E.coli 
 
For amplification of generated recombinant plasmids, electrocompetent 
bacteria (Electromax electrocompetent DH10B bacteria, Invitrogen) were 
transformed by electroporation. Transformation is achieved by applying an 
electric current of 1.8 kV that causes poration of the cell membrane and thus 
allows a very efficient uptake of foreign DNA. 
Precipitated ligated DNA (see materials and methods 4.1.7) was mixed with 25 
µl of freshly thawed electrocompetent bacteria and incubated on ice for 5 min. 
The mixture was pipeted into a 1 mm pre-cooled electroporation cuvette 
(Biozym) and immediately electroporated at 1.8 kV (BioRad Pulse Controller 
Plus) followed by a quick uptake in 1 ml of 37°C pre-warmed SOC medium 
(Invitrogen). Transformed bacteria were incubated for 1 hour at 37°C on a 
shaker. Subsequently 100 µl of the suspension were plated on an agar plate 
containing suitable antibiotics for proper selection of successfully transformed 
bacteria and further incubated at 37°C over night. 
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4.1.9 Bacterial culture media and agar plates  
 
Growth media and agar plates contained L-Broth medium (LB) as a main 
component and were prepared in 5 l batches. 
 
LB medium : 1%  NaCl 
 1%  Select peptone 140 
 0.5%  Yeast extract 
 pH 7.5 using 10 M NaOH 
 
Agar plates : 15 g Bacterial grade agar (Difco) 
 1 l  LB medium 
 antibiotic for selection (for example ampicillin 100 mg/ml) 
 
Bacterial grade agar was dissolved in LB medium, autoclaved and allowed to 
cool down to 50°C, then the heat sensitive antibiotic was added. The mixture 
was poured into bacterial culture dishes with 10 cm in diameter and after 
hardening of the agar, plates were stored at 4°C for mid-term use. 
 
4.1.10 Plasmid extraction in small scale (Miniprep) 
 
After transformation, plasmids had to be isolated out of bacterial clones and 
checked for integrity. Therefore, a single colony was picked from the agar 
plate and inoculated in 3 ml LB-medium containing the corresponding 
antibiotic and incubated at 37°C under constant shaking over night. The next 
day, 1.5 ml of the bacterial culture were harvested by centrifugation at 4000 x 
g for 5 min. The bacterial pellet was resuspended in 300 µl resuspension 
buffer P1 and incubated at room temperature for 5 min. 300 µl of lysis buffer 
P2 were added, the tube mixed by inverting and incubated at room 
temperature for 5 min following addition of 300 µl neutralisation buffer P3. The 
lysate was centrifuged at 16000 x g for 30 min and plasmid containing 
supernatant was transferred to a new 1.5 ml polypropylene tube. Addition of 
650 µl isopropanol led to precipitation of DNA which was spun down by 
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centrifugation at 16000 x g for 30 min. The supernatant was discarded and the 
DNA-containing pellet washed in 500 µl 70% ethanol. The DNA pellet was 
spun down again, the supernatant discarded and the plasmid DNA-containing 
pellet resuspended in 50 µl ddH2O. DNA concentration was determined (see 
materials and methods 4.1.5) and restriction endonuclease test digests were 
carried out (see materials and methods 4.1.2). 
 
Resuspension buffer P1 : 50 mM Tris-HCl pH 8.0 
  10 mM EDTA 
  100 mg/ml RNase A 
 
Lysis buffer P2 :  200 mM NaOH 
  1% SDS (w/v) 
 
Neutralisation buffer P3 : 3 M KCl 
  pH 5.5 adjust with glacial acetic acid 
 
4.1.11 Plasmid extraction in large scale (Maxiprep) 
 
When plasmids were found to be correct after the test digest, a large scale 
plasmid extraction was performed using the Qiagen Plasmid Maxi Kit. 
Therefore the 1.5 ml left over of miniprep over night culture was used to 
inoculate 200 ml of LB medium containing the appropriate antibiotic. The 200 
ml culture was incubated in a 2 l Erlenmeyer flask under vigorous shaking over 
night at 37°C. If necessary, 5 ml of the culture were taken and frozen as a 
bacterial stock at -20°C or -80°C for further processing. The bacteria were 
harvested by centrifugation at 6000 x g for 15 min. After discarding the 
supernatant, the bacterial pellet was resuspended in 10 ml of resuspension 
buffer P1 (Qiagen). After 5 min, 10 ml of lysis buffer P2 (Qiagen) were added, 
the sealed tube inverted several times and incubated for exactly 5 min at room 
temperature. For neutralisation, 10 ml of neutralisation buffer P3 (Qiagen) 
were added and the lysate incubated on ice for 20 min. The bacterial debris 
was spun down first at 20000 x g for 30 min and a second time at 20000 x g 
                                                                                        Materials and Methods 
 28 
for 15 min, both at 4°C and subsequently the plasmid-containing supernatant 
was applied to a QIAGENtip 500, previously equilibrated with 10 ml 
equilibration buffer QBT (Qiagen). The column was washed twice with 30 ml of 
washing buffer QC (Qiagen) and finally bound plasmid DNA was eluted with 
15 ml of elution buffer QF (Qiagen). For precipitation of eluted plasmid DNA, 
10.5 ml of isopropanol were added and precipitated DNA collected by 
centrifugation at 4°C with 15000 x g for 30 min. Supernatant was discarded 
and the pellet washed with 5 ml of 70% EtOH. Again the pellet was spun down 
at 15000 x g for 10 min at 4°C and the supernatant decanted. The plasmid 
DNA-containing pellet was air dried in an Eppendorf Speed-Vac vacuum dryer 
and resuspended in 200 µl ddH2O. DNA concentration was measured (see 
materials and methods 4.1.5) and restriction endonuclease test digests were 
carried out (see materials and methods 4.1.2). 
 
Buffer P1, P2, P3 :  see materials and methods 4.1.10 
 
Equilibration buffer QBT : 750 mM NaCl 
  50 mM 3-(N-morpholino)propanesulfonic 
   acid (MOPS) pH 7.0 
  15% Isopropanol (v/v) 
  0.15% Triton X-100 (v/v) 
 
Wash buffer QC :  1 M NaCl 
  50 mM MOPS pH 7.0 
  15% Isopropanol (v/v) 
 
Elution buffer QF :  1.25 M NaCl 
  50 mM Tris-HCl pH 8.5 
  15% Isopropanol (v/v) 
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4.1.12 Long term storage of bacteria 
 
For long term storage 1.2 ml of the bacterial over night culture were mixed with 
200 µl of 80% glycerol and then stored at -80°C. 
 
4.1.13 Isolation of genomic DNA from eukaryotic cells 
 
For isolation of genomic DNA from cultured cells, the DNeasy Blood & Tissue 
Kit (Qiagen) was used. A maximum of 5x106 cells were harvested by 
centrifugation at 300 x g for 5 min. The pellet was resuspended in 200 µl of 
PBS and then 20 µl of proteinase K (800 U/ml, Sigma) were added. After 
addition of 200 µl buffer AL (Qiagen), cells were mixed by vortexing and 
incubated at 56°C for 10 min. 200 µl of absolute ethanol were added and the 
sample vortexed again. The mixture was pipetted into a DNeasy Mini spin 
column (Qiagen) and centrifuged at 6000 x g for 1 min. Flow-through was 
discarded and 500 µl of buffer AW1 (Qiagen) added, followed by centrifugation 
at 6000 x g for 1 min. Again the flow-through was discarded and 500 µl of 
buffer AW2 (Qiagen) added. After centrifugation at 20000 x g for 3 min and 
discarding the flow-through, the bound DNA was eluted by addition of 200 µl 
buffer AE (Qiagen), incubation for 1 min and centrifugation at 6000 x g for 1 
min at room temperature. The DNA concentration was determined as 
described in 4.1.5. 
   
4.1.14 Isolation of cellular RNA 
 
The QIAGEN RNeasy Mini Kit was used for isolation of total cellular RNA. Up 
to 1x106 cells were treated in one purification step. First, cells were trypsinised 
(see materials and methods 4.3.2) and harvested by centrifugation at 300 x g 
for 5 min. The supernatant was aspirated completely and cells were disrupted 
by adding 350 µl of buffer RLT (Qiagen) followed by vortexing. For 
fragmentation of genomic DNA, the lysate was transferred into a QIAshredder 
spin column (Qiagen) and centrifuged for 2 min at full speed (Eppendorf table 
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top centrifuge). 350 µl of 70 % ethanol were added, mixed well by pipetting 
and transferred to an RNeasy spin column (Qiagen) followed by centrifugation 
at 8000 x g for 15 sec. After discarding the flow-through, 700 µl of buffer RW1 
(Qiagen) were added and again centrifugation was performed at 8000 x g for 
15 seconds. Flow-through was discarded. 500 µl of buffer RPE (Qiagen) were 
added and centrifugation performed at 8000 x g for 2 min. Flow-through was 
discarded and, to get rid of any residual buffer, centrifugation was performed 
again at full speed for 1 min. The  RNeasy spin column was placed in a new 
1.5 ml polypropylene tube, 50 µl of RNase-free ddH2O (Qiagen) were added 
directly to the membrane and RNA eluted by centrifugation at 8000 x g for 1 
minute. Concentration of RNA was determined as described in 4.1.5. 
 
4.1.15 In vitro transcription of RNA 
 
For the stepwise approach of establishing the StreptoTag method from in vitro 
to in vivo conditions, first, in vitro transcribed RNA was used. RNA was 
produced using the T7 RiboMAX Express Large Scale RNA production system 
(Promega). Prior to RNA synthesis, the DNA template had to be linearised 
(see materials and methods 4.1.2) in order to produce a run-off transcript 
starting at the T7 promoter of the RNA encoding vector. After linearisation, the 
DNA was purified from the agarose gel (see materials and methods 4.1.4). Up 
to 1 µg of DNA was used as a template. Components were mixed gently and 
incubated at 37°C for 1 hour followed by RNA cleanup (see materials and 
methods 4.1.14) and determination of RNA concentration (see materials and 
methods 4.1.5). In vitro transcribed RNA was stored in aliquots of 100 µg at -
80°C. 
 
T7 Reaction Components : 10 µl RiboMAX 2 x buffer 
  1 µg linear DNA template 
  2 µl T7 Enzyme Mix 
  ddH2O up to 20 µl 
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4.1.16 Denaturing RNA gel electrophoresis 
 
A denaturing RNA gel electrophoresis was performed because most RNAs 
form complex secondary structures by intramolecular base pairing and 
therefore do not migrate through the gel strictly according to their size. By 
applying an electric current, negatively charged nucleic acids migrate through 
the agarose gel to the cathode, corresponding to the expected size of the 
fragment to be analysed. Smaller fragments are less retained in movement 
and therefore migrate faster than larger ones. For preparation of the gel, 2 g of 
agarose were mixed with 180 ml of DEPC-treated water followed by cooking in 
a microwave oven at 750 W until the agarose was dissolved completely. The 
gel was left on the magnetic stirrer for 10 min to cool down below 50°C and 
then 20 ml of 10x MOPS as well as 7 ml formaldehyde were added. Before 
pouring the gel, the chamber had to be washed and maintained RNAse free. 
Therefore, the chamber was incubated 10 min with 5% SDS and then washed 
with ddH2O. After incubation with 3% H2O2 for further 10 min, the chamber 
was washed twice with DEPC ddH2O. Upon this procedure, the previously 
prepared gel was poured into the chamber and allowed to solidify. As running 
buffer 1x MOPS in DEPC-treated ddH2O was used. The RNA samples were 
mixed with a denaturing 2x RNA loading dye (Fermentas) and heated for 10 
min at 70°C followed by centrifugation to collect evaporated sample which 
were kept on ice until loading.   
 
DEPC-treated water : 5 ml  Diethylpyrocarbonate 
  5 l ddH2O water 
  stirring 
  autoclave 
 
10x MOPS :  41.8 g MOPS 
  4.1 g NaAc 
  40 ml 0.5 M EDTA pH=8 
  fill to 1 l with DEPC ddH2O => pH=7 (NaOH) 
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4.2 Purification of recombinant proteins by affinity 
chromatography 
 
4.2.1 Expression of recombinant proteins 
 
Large scale expression of recombinant proteins for subsequent automated 
His-tag affinity purification was carried out in Escherichia coli BL21(DE3). 
Expression was driven by a T7 promoter, controlled by an Isopropyl β-D-1-
thiogalactopyranoside (IPTG) inducible lac-operon. First, 50 µl of an already 
characterised single clone of transformed bacteria were incubated in 2 ml LB 
containing the appropriate antibiotic at 37°C on a shaker at 200 rpm. After 2 
hours, a total of 2 ml were used to inoculate 75 ml of LB medium, also 
containing antibiotics for selection, which were then incubated at 37°C over 
night with continuous shaking at 170 rpm in a 0.5 l Erlenmeyer flask. The 
following day, 5 ml of the over night culture were used to inoculate 200 ml LB 
medium without antibiotics in a 1 l flask. At OD600 = 0.6, an aliquot of 1 ml 
was taken out (non-induced control) and IPTG was added to the 200 ml 
culture to a final concentration of 1 mM. Induction was carried out by 
incubation at 37°C with 175 rpm on an orbital shaker. After 3 hours, bacteria 
were harvested by centrifugation at 6000 x g for 15 min at 4°C. The resulting 
pellet of approximately 1 g in weight was either frozen at -20°C for mid-term 
storage or directly processed for protein purification.  
 
4.2.2 Preparation of bacterial samples for automated His-Tag affinity 
purification 
 
The bacterial pellet was resuspended in 5 ml of washing buffer (see materials 
and methods 4.2.4) and after addition of 50 µl of protease inhibitor cocktail 
(Sigma-Aldrich P8340), lysozyme was added to a final concentration of 2 
mg/ml. The bacterial suspension was vortexed briefly, then shaked at room 
temperature for 20 min. For further destruction of bacteria, they were sonified 
for 2 min on ice using the Bandelin UW2070 with a MS73 tip followed by a 10 
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sec vortex step and shaking on ice for 10 min. This procedure was carried out 
twice. MgCl2 was then added to a final concentration of 20 mM per gram tissue 
as well as Benzonase nuclease (DNAse/RNAse, Novagen) to a final 
concentration of 500 units per gram tissue. The mixture was again incubated 
under vigorous shaking for 15 min at room temperature. Bacterial debris was 
spun down by centrifugation at 18000 x g for 20 min at 4°C. To prevent 
clogging of the column, the protein containing supernatant was filtered through 
a 0.45 nm filter (Millipore) and finally diluted in 25 ml of washing buffer. To 
increase the yield of purified protein, the expression approach was carried out 
in duplicates, which were combined after the filtration step and diluted in 50 ml 
washing buffer. The total amount was loaded into the ÄKTAprime superloop 
and the purification carried out as described in 4.2.4. Fractions were stored at 
4°C until those containing the protein of interest were determined by Western 
blot analysis (see materials and methods 4.6). 
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4.2.3 Technical equipment : ÄKTAprime plus FPLC 
 
 
Figure 4.2.3. Schematic view of ÄKTAprime plus FPLC. The unit includes the control 
system, a pump, a fraction collector, and valves for buffer selection, sample injection, gradient 
formation and flow diversion. Furthermore, the unit used was equipped with a superloop 
placed in the column holder to allow application of samples of up to 50 ml (from ÄKTAprime 
plus Operating Instructions 28-9597-89 AA). 
 
ÄKTAprime plus is a compact fast protein liquid chromatography system for 
purification of proteins in lab scale. Recombinant protein was obtained by 
inducing expression in transformed bacteria (for expression plasmids see 
appendix 8) as described in 4.2.1, followed by isolation of total protein from 
bacteria as described in 4.2.2. 
 
4.2.4 His-Tag affinity purification  
 
Recombinant proteins carrying a polyhistidine-tag (His-Tag) can be purified by 
their interaction with metal ions which are contained in the affinity medium 
(Hochuli 1988; Hengen 1995). For native purification of histidine-tagged 
proteins, the sample was injected in a volume of 50 ml into the injection valve 
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and loaded into the superloop. Affinity purification was carried out 
automatically  using a 5 ml HisTrap FF pre-packed column (GE Healthcare) by 
running a predefined program depicted below. To avoid copurification of 
bacterial proteins, the recombinant His-tagged protein was purified with 
stringent conditions using buffers containing imidazole in concentrations of 
200 mM (washing buffer) and 1 M (elution buffer), respectively. 
 
 
Figure 4.2.4. Affinity chromatography using a His-Tag. Method performed on a ÄKTAprime 
plus for native purification of histidine-tagged proteins. Volume is given in ml and flow in 
ml/min (from ÄKTAprime plus User Manual 11-0026-44 AA). 
 
Washing buffer :  20 mM  Sodium phosphate buffer  
   pH 7.4 
  0.5 M NaCl 
  200 mM Imidazole 
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Elution buffer :  20 mM  Sodium phosphate buffer  
   pH 7.4 
  0.5 M NaCl 
  1 M  Imidazole 
 
4.2.5 Concentration of fractionated protein samples 
 
Fractions containing high amounts of protein of interest were determined by 
Western blot analysis (see materials and methods 4.6). Protein from those 
fractions was concentrated using centrifugal concentration units (Vivaspin) 
with a molecular weight cut off (MWCO) of 3 kDa. The unit was filled with the 
respective eluate and centrifugation was performed in a swinging bucket rotor 
at 5000 x g at 4°C. Finally fractions were concentrated by consecutive 
centrifugation steps, the imidazole-containing elution buffer was exchanged by 
a 20 mM sodium phosphate buffer to ensure protein stability. Protein 
concentration was determined in a Lowry assay (see materials and methods 
4.2.6). The concentrate of about 200 µl was aliquoted and stored as described 
in 4.2.7. 
 
4.2.6 Determination of protein concentrations 
 
Protein concentration was determined using a Lowry protein assay kit  (Bio-
Rad), (Lowry, Rosebrough et al. 1951). The higher the protein content in a 
given solution, the stronger the detectable change in color caused by 
reduction of copper ions through peptide bonds. Therefore 5 µl of each sample 
were pipetted in duplicates into a 96 well plate (Sarstedt - flat bottom) as well 
as the standard consisting of bovine serum albumin (BSA) in a range from 0.1 
to 1.0 µg/µl. 25 µl of reagent A (Bio-Rad), an alkaline copper tartrate solution, 
supplemented with 2% of reagent S (Bio-Rad) was added, followed by addition 
of 200 µl of reagent B (Bio-Rad). The samples were incubated for 20 min at 
room temperature and absorbance was measured at 630 nm. Protein 
concentration was calculated comparing OD values of samples to those of the 
standard containing known BSA concentrations.  
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4.2.7 Long term storage of proteins 
 
For long term storage, proteins in 20 mM sodium phosphate buffer pH = 7.4 
were mixed with glycerol to a final concentration of 25% to preserve 
functionality after thawing. Aliquots were stored at -80°C.  
 
4.3 Cultivation of eukaryotic cells 
 
4.3.1 Cell lines 
 
HEK293 cells (ATCC CRL-1573) : 
The HEK293 cells are a hypotriploid cell line originating from human 
embryonic kidneys, which was established by transformation with adenovirus 
type 5 (Louis, Evelegh et al. 1997). A subcultivation of 1:10 to 1:20 and a 
medium renewal 2-3 times per week is recommended by ATCC. 
 
CrFK cells (ATCC CCL-94) : 
This cell line is derived from feline kidneys (Crandell, Fabricant et al. 1973). A 
subcultivation of 1:3 to 1:8 and a medium renewal 2-3 times per week is 
recommended by ATCC. 
 
4.3.2 Cultivation 
 
Normal medium (NM) :  Dulbecco’s modified eagle medium  
   (DMEM) with high glucose (GlutaMAX) 
   and 10% heat inactivated Fetal Calf  
   Serum (FCS) 
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Trypsin-EDTA :   8.0 g/l NaCl 
   0.4 g/l KCl 
   0.35 g/l NaHCO3 
   0.726 g/l Na2HPO4 – 7H2O 
   1.0 g/l D-Glucose 
   0.2 g/l EDTA 
   0.5 g/l Trypsin 
   0.005 g/l Phenol red in ddH2O 
Phosphate buffered saline (PBS) : 1.06 mM  KH2PO4 
   155.17 mM  NaCl 
   2.97 mM  Na2HPO4 – 7H2O 
   pH 7.4 
 
All working steps with cells were carried out under sterile conditions using a 
laminar air flow hood (Nuaire), and single-use liquid handling equipment 
(Sarstedt). The laminar air flow hood as well as all equipment used was 
cleaned prior to work using 70% ethanol, and the hood was sterilised 
afterwards by exposure to UV radiation for 20 min. 
Media, FCS and trypsin were purchased from Invitrogen. Cells were cultured 
in polypropylene plastic flasks T75 (75 cm2) or T175 (175 cm2); (Greiner or 
Sarstedt) with a specially treated surface to facilitate cell adherence. Phenol 
red added to the normal medium served as an indicator for pH change. A 
yellow shift indicated an acidic environment and a medium change had to be 
performed. The cells were cultivated at 37°C with an atmosphere containing 
5% CO2.  
To passage cells, the old medium was removed first and cells washed with 5 
ml of PBS to get rid of excess FCS which lowers activity of trypsin which is 
used to detach cells by digesting cell-cell and cell-matrix interactions. 3-4 ml of 
trypsin-EDTA were incubated with the cells at 37°C for 5 min. Protease activity 
was neutralised by adding an excess of normal medium containing 10% FCS. 
Cells were split in ratios as recommended by the supplier, the american type 
culture collection (ATCC). One part of the cells was discarded and the other 
incubated in fresh medium. This procedure was defined as one passage.  
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4.3.3 Determination of cell number 
 
To achieve a high transfection efficiency, an exact density of seeded cells is a 
prerequisite. Therefore, trypsinised cells were resuspended properly in 10 ml 
of medium. 100 µl were diluted in 900 µl of medium and thereof one drop was 
loaded in duplicates to a 16 square disposable haemocytometer (FastRead, 
Megumed Diagnostics). 2 x 3 squares were counted using a microscope 
(Olympus) and the average value calculated. This number was multiplied with 
104 to equal the number of cells contained in 1 ml of the solution. 
 
4.3.4 Freezing and thawing 
 
To ensure integrity of cells used, they were discarded after 30 passages and 
therefore a frozen stock of cells had to be kept. The stock was prepared by 
harvesting cells grown to confluence in a T175 cell culture flask. After 
detaching, cells were centrifuged at 300 x g for 5 min, washed with 10 ml PBS 
and centrifuged again following resuspension in 3 ml of freezing medium. 
Aliquots of 1 ml were prepared and slowly cooled from room temperature to 
0°C on blue ice for 30 min. A freezing container (“Mr.Frosty”, Nalgene) was 
used to cool cells down to -80°C at a cooling rate of -1°C/min which is required 
for successful cell cryopreservation.  
Cells were thawed by resuspension in warm normal medium, followed by 
centrifugation at 300 x g for 5 min to get rid of dimethyl sulfoxide (DMSO). The 
pellet was resuspended in 10 ml normal medium and transferred to a T75 
flask. 
 
Freezing medium :  10% Dimethylsulfoxide (DMSO) 
  30% FCS 
  60% Normal medium (NM) 
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4.3.5 Transfection 
 
The process known as transfection is used to introduce heterogenic DNA or 
RNA into cells. To  facilitate endocytosis of DNA into cells, transfection 
reagents such as cationic lipids are used which form complexes with 
negatively charged DNA. Once in the cytoplasm, uptaken plasmid DNA can 
access the nucleus during cell division where any gene driven by a 
mammalian promoter will be transcribed.  
Lipofectamine 2000 (Invitrogen) was used as a transfection reagent. All 
transfections were carried out with cells grown either in 10 cm dishes or in 6-
well plates (Sarstedt). Cells were seeded 24 hours prior to transfection and 
further grown to 90-95% confluence to allow efficient transfection. A maximum 
of 25 µg of DNA and 60 µl of Lipofectamine 2000 were incubated separately in 
1.5 ml of FCS-free DMEM. After 5 min, DNA was mixed with the transfection 
reagent and incubated for further 20 min to allow formation of DNA-
lipofectamine complexes. Subsequently the solution was applied dropwise to 
the cells and mixed by shaking the plate 5 times cross-wise. After 8 hours, the 
medium was exchanged to remove excessive Lipofectamine 2000. 
Transfected cells treated this way were analysed 48 hours later. 
 
4.3.6 Crude preparation of cell lysates 
 
For isolation of proteins and RNA from eukaryotic cells, cytoplasmic fractions 
and nuclear cell fractions were prepared.  
Transfected HEK293 cells grown in a 10 cm dish were trypsinized (see 
materials and methods 4.3.2) and centrifuged at 300 x g  for 5 min. Medium 
was removed, cells washed with 5 ml of PBS and centrifuged again. The cell 
pellet was resuspended in 200 µl of lysis buffer containing 
octylphenoxypolyethoxyethanol (IGEPAL - Sigma) as a detergent. 8 µl of 
RNAsin plus RNAse inhibitor (40 U/µl - Promega) and 5 µl of protease inhibitor 
cocktail (Sigma-Aldrich P8340) were added and the sample vortexed 
immediately until cells were lysed completely and the solution turned opaque. 
The lysate was centrifuged at 3000 x g for 5 min at 4°C and the supernatant 
                                                                                        Materials and Methods 
 41 
containing the cytoplasmic fraction was stored at 4°C. The pellet containing 
the nuclei was substituted with 4 µl RNAsin Plus RNAse Inhibitor and 5 µl of 
protease inhibitor cocktail (Sigma-Aldrich P8340) and 100 µl of protein 
isolation buffer were added to resuspend the nuclear fraction. For proper lysis, 
the solution was kept on ice and vortexed every 5 min for 10 seconds over 1 
hour. Cellular debris was spun down at 12000 x g for 15 min at 4°C and the 
supernatant was transferred to a new tube. Fractions were unified, incubated 
for 15 min and loaded onto the column. 
 
IGEPAL lysis buffer :  50 mM Tris-HCl pH 7.5 
  140 mM NaCl 
  1.5 mM MgCl2 
  0.5%  IGEPAL 
  5 mM  Dithiothreitol (DTT)  
    (freshly added) 
 
Protein isolation buffer : 10 mM Tris-HCl pH 7.8 
  0.4 M  NaCl 
  1 mM  DTT (freshly added) 
  0.2 mM Phenylmethanesulfonyl 
    fluoride (PMSF) (freshly
    added) 
 
4.4 Fluorescence activated cell sorting (FACS) 
 
To ensure a maximum expression level of the protein and / or RNA to be 
purified by affinity chromatography, transfection efficiency needed to be 
sufficiently high. To determine transfection efficiencies, cells were co-
transfected with pCMVGFP, an expression vector encoding green fluorescent 
protein, in addition to the expression plasmids encoding the protein and RNA 
of interest. The amount of fluorescent cells, which represents the number of 
successfully transfected cells, was determined using a FACSCalibur (Becton, 
Dickinson) flow cytometer. 
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Measurement was carried out by exciting fluorescence using a monochromic 
blue argon laser (488 nm wave length). The number of fluorescent cells 
detected divided by the over all amount of cells measured was referred to as 
efficiency of transfection. 
 
4.5 StreptoTag affinity purification 
 
After nuclear/cytoplasmic fractionation of cells the lysate was subjected to 
affinity chromatographic purification using a streptomycin-coupled sepharose.
  
4.5.1 Coupling of sepharose with streptomycin  
 
For the coupling reaction, 5 g of epoxy-activated sepharose 6B (GE 
Healthcare) were dissolved in 1 l of cell culture grade H2O and incubated for 1 
hour at room temperature with gentle movement on a magnetic stirrer. 
Thereafter, the dispersion was filtered through a 40 – 100 µm sintered glass 
filter (Schott) and the sepharose resuspended in 50 ml of 98% ethanol 
followed by four consecutive washing steps with 50 ml of coupling buffer. The 
washed column material was incubated for 16 hours in 25 ml of coupling 
buffer containing 1 mM of dihydrostreptomycin with gentle movement on an 
orbital shaker at 37°C. Dihydrostreptomycin (Sigma) was used as the 
coupling reaction occurs in 10 mM NaOH and streptomycin would undergo 
irreversible hydrolysis under these pH conditions (Bachler, Schroeder et al. 
1999). Again, coupled sepharose was filtered through a 40 – 100 µm sintered 
glass filter and washed four times with 50 ml of column buffer. For 
regeneration of the coupled sepharose, alternating washing steps were 
carried out using a low pH-buffer (pH 4.0) and a high pH-buffer (pH 8.3) three 
times each. Finally, the dihydrostreptomycin-coupled sepharose was washed 
four times with 50 ml cell culture grade H2O and stored in 50 ml of ddH2O at 
4°C. To prevent bacterial growth, 250 µl of 10% sodium azide were added. 
Column material was used within one month after coupling.  
 
                                                                                        Materials and Methods 
 43 
5 x Column buffer :  25 mM MgCl2 
  250 mM Tris-HCl (pH 7.6) 
  1.25 M NaCl 
 
Coupling buffer :  10 mM NaOH 
  pH 12.0 
 
Low pH buffer :  0.1 M  Sodium acetate 
  0.5 M  NaCl 
  pH 4.0 
 
High pH buffer :  0.1 M  Sodium hydrogen carbonate 
  0.5 M  NaCl 
  pH 8.3 
 
4.5.2 Affinity purification of RNA binding proteins 
 
Prior to filling the coupled sepharose into the Poly-Prep columns (9 cm high, 2 
ml bed volume, 10 ml reservoir; Bio-Rad), the column was flushed with 5 ml of 
column buffer. 2 ml of the coupled sepharose were pipetted into the column 
and flushed four times with 2 ml of column buffer. To block unspecific RNA 
binding sites, 10 µg of tRNA diluted in 1 ml of column buffer were applied to 
the column. When in vitro transcribed RNA was used for affinity purification, 
RNA was refolded after thawing by incubation at 65°C for 8 min, 37°C for 8 
min and finally at room temperature for 8 min. 100 µg of tRNA were added to 
the protein solution and unified with the refolded target RNA. In the next step, 
RNA and protein mixtures were combined followed by incubation for 20 min at 
room temperature to allow RNA - protein interaction to occur. The solution was 
diluted in column buffer to a final volume of 4 ml and loaded onto the column 
in 4 aliquots to 1 ml each within 8 min. The flow-through of 4 ml was kept and 
applied in a single step a second time to enhance the amount of RNA and 
protein retained. Five washing steps with 2.5 ml of column buffer were 
performed prior to elution with 3 ml of 1 mM streptomycin in column buffer. 
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Fractions were precipitated with acetone (see materials and methods 4.5.3). 
Used columns were washed with 8 ml of column buffer and stored in 3 ml of 
column buffer at 4°C. 
 
4.5.3 Concentration of fractionated proteins 
 
Protein contained in the different fractions eluted from streptomycin-coupled 
sepharose was concentrated by adding 4 volumes of ice cold (-20°C) acetone. 
Glass tubes (15 ml, Corex) were sealed with a foil (Parafilm), shaked 
vigorously and quickly put on -80°C for 30 min. After incubation at -20°C over 
night, the protein precipitated was instantly centrifuged at 4°C for 30 min at 
25000 x g (Avanti J25 - Beckman - Coulter) using a swinging bucket rotor. 
Supernatant was discarded carefully and the pellet was dried in a vacuum 
dryer for 5 min and resuspended in 40 µl of 1 x protein sample buffer. The 
sample was stored at -20°C for further analysis. 
 
4.6 Western blot analysis 
 
4.6.1 SDS-polyacrylamide gel electrophoresis 
 
A sodium dodecyl sulfate (SDS)-polyacrylamide gel is used for separation of 
proteins. It usually consists of two functional parts: the resolving gel, in which  
proteins are seperated, is covered by a stacking gel in which samples are 
loaded and concentrated. For the present work, 12% acrylamide was used for 
the resolving gel and 5% for the preparation of the stacking gel. 
Preparation of SDS-polyacrylamide gels was carried out in a Hoefer SE 260 
Mighty Small II (GE Healthcare) dual gel casting unit. After pouring the 
resolving gel, it was covered by 1 ml of isopropanol to prevent it from drying. 
Polymerisation was allowed for about 20 min and then the gel was washed 
with ddH2O to remove the isopropanol and finally traces of H2O were removed 
using a Whatman paper (3MM Whatman). Subsequently, the stacking gel was 
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poured and allowed to polymerise for 20 min. Finally, gels were placed in a 
Hoefer Mighty Small II SE 250/260 mini vertical electrophoresis unit (GE 
Healthcare) and submergered in 1 x Laemmli buffer. 
The samples were mixed 1:1 with a 2 x protein sample buffer and heated at 
95°C for 5 min to irreversibly denature secondary structures of proteins. Up to 
40 µl were loaded into each slot, except of the marker (PageRuler prestained 
protein ladder - Fermentas), of which 3 µl were used. Electrophoresis of a 12% 
gel was performed at 90 V for exactly 1 hour and 50 min.  
 
Stacking gel (5%) :  3.75 ml  ddH2O 
  625 µl  Tris-base pH 6.8 
  625 µl  40 % acrylamide 29:1 (Bio-Rad) 
  25 µl  20% SDS 
  30 µl   10% Ammoniumpersulfate (APS) 
  10 µl   Tetramethylethylenediamine  
    (TEMED, Bio-Rad) 
 
Resolving gel (12%) : 3.7 ml  ddH2O 
  4.8 ml  Tris-base pH 8.8 
  3.6 ml  40 % acrylamide 29:1 (Bio-Rad) 
  64 µl  20% SDS 
  66 µl   10% APS 
  10 µl   TEMED (Bio-Rad) 
 
10 x Laemmli buffer :  0.25 M Tris-base 
  1.92 M Glycin 
  1%  SDS (w/v) 
 
Protein sample buffer :  0.12 M Tris-HCl pH 6.8 
  4%  SDS (w/v) 
  20.23% Glycerol (w/v) 
  0.016% Bromphenol blue (w/v) 
  1.47 M β-Mercaptoethanol 
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4.6.2 Blotting and immunostaining 
 
Blotting of the gel was performed in a Hoefer TE70 semi dry transfer unit (GE 
Healthcare). Therefore, 6 pieces of Whatman paper in the same size as the 
gel (62 mm x 83 mm) and one 0.45 µm Hybond P Polyvinylidne fluoride 
(PVDF) transfer membrane (GE Healthcare) were prepared. The stacking gel 
was removed and the resolving gel washed in transfer buffer for 5 min. The 
membrane was first soaked in pure methanol for 15 seconds, following a 5 
minute washing step in ddH2O and finally 5 min of washing in transfer buffer. 
The blotting sandwich was built by soaking 3 Whatman paper in transfer buffer 
and placing them on to the transfer unit, followed by the transfer membrane, 
the gel and another three soaked Whatman papers. To prevent formation of 
air bubbles, half of a disposable 10 ml polypropylene pipette (Sarstedt) was 
used to roll over each layer of the sandwich. Blotting was carried out at 20 V 
(upper limit) and 1.1 mA/cm2 of membrane for 1 hour and 10 min. 
After blotting, the membrane was blocked over night in 5 % milk powder in 
TTBS at 4°C on a horizontal shaker. The gel was stained with AgNO3 as 
described in materials and methods, 4.6.4. The next day, the membrane was 
directly incubated with the primary antibody which was diluted in 5 ml TTBS 
containing 2.5% milk powder. Placed in a 50 ml polypropylene tube (Falcon), 
the membrane was incubated in a rotator (Biometra Compact Line OV4) at 
room temperature. After 1 hour of incubation, the membrane was washed with 
TTBS 5 times, followed by incubation with the horseradish peroxidase (HRP)-
conjugated secondary antibody. Also the secondary antibody was diluted in 5 
ml TTBS containing 2.5% milk powder. After one hour of incubation at room 
temperature, the membrane was washed 3 times with TTBS and 2 times with 
TBS (Tris-buffered saline) to get rid of excess Tween-20 that could interfere 
with the detection of chemiluminescence. 
For detection of HRP-conjugated secondary antibodies bound to primary 
antibodies that are interacting with proteins blotted onto the membrane, the 
ECL-plus Western blot detection system (GE Healthcare) was used. For each 
membrane, 2 ml of solution A (ECL Plus substrate solution containing Tris-HCl 
buffer) were mixed with 50 µl of solution B (acridian stock solution in dioxane 
and ethanol) and warmed up to room temperature. The membrane was 
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carefully rinsed with the solution for 5 min in a plastic tray and transferred to a 
transparent plastic foil which was placed in a developing film cassette. Finally 
the membrane was exposed to an X-ray film (Hyperfilm ECL - GE Healthcare) 
for an appropriate period of time. The film was developed using an AGFA 
Curix 60 automatic developer.  
 
Transfer buffer :  192 mM Glycine 
  25 mM Tris-base 
  20%  Methanol (v/v) 
  pH 8.3 
 
Blocking solution :  5%  Non-fat dry milk 
  in 1 x TTBS 
 
10 x TTBS :  0.1 M  NaCl (w/v) 
  20 mM Tris-base pH 8.8 
  0.01%  Tween-20 (Bio-Rad) 
 
10 x TBS :  0.1 M  NaCl (w/v) 
  20 mM Tris-base pH 8.8 
 
4.6.3 Silver staining of proteins 
 
After semidry blotting, the gel was stained with AgNO3. This is a fast and very 
sensitive method for detection of proteins. The gel was fixed in 50% methanol 
and 5% acetic acid for 20 min on a shaker followed by incubation in 50% 
methanol for 10 min. The gel was then washed with ddH2O over night. On the 
next day the gel was sensitised in 0.02% Na2S2O3 for 1 minute followed by 2x 
washing in ddH2O for 1 minute each. Afterwards, the gel was incubated in cold 
0.1% AgNO3 for 20 min. To remove excess AgNO3 two washing steps in 
ddH2O for 1 minute each were performed. Finally, the gel was developed in 
0.04% formalin and 2% Na2CO3 for 2-5 min. Staining of the gel was terminated 
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by incubation in 5% acetic acid for 10 min. For mid-term use, the gel was 
stored at 4°C in 1% acetic acid. 
 
4.7 Polymerase chain reactions 
 
4.7.1 Primer design 
 
Oligonucleotide primers for use in polymerase chain reaction (PCR) 
amplification were designed virtually using the software Clone Manager 5 as 
described in materials and methods, 4.1.1. Specifications for design of primers 
were given by the guanosine to cytosine content which should range between 
50% and 60%. Primer sequences were submitted online and ordered from 
Microsynth (Switzerland). 
  
4.7.2 PCR amplification 
 
For selectively amplifying a specific DNA sequence, PCR was performed 
using specifically designed primers. For performing analytical PCR, Taq DNA 
polymerase derived from Thermus aquaticus, without proof-reading activity 
was used. 
 
PCR master mix for Taq DNA polymerase : 
  10 mM each dNTP 
  100 pmol/µl forward and reverse primers 
  10 µl  5 x GoTaq buffer (Promega) 
  2 U  Taq DNA polymerase 
  5 – 10 ng  DNA template 
  ddH2O up to 50 µl 
 
For PCR amplification either the Gene Amp PCR System 9700 (Applied 
Biosystems) or peqSTAR 96 (Peqlab) were used. For analytical PCR the 
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following standard amplification was carried out (step 1, denaturation; step 2, 
denaturation-primer annealing-elongation; step 3, elongation; step 4, storage) :  
 
Profile step 1 step 2 (x 30) step 3 step 4 
Temp 95°C 95°C 55°C 72°C 72°C 4°C 
Time 2 min 30 sec 30 sec 1 min 7 min hold 
 
Subsequently up to 20 µl were withdrawn for analysis by agarose gel 
electrophoresis as described in materials and methods, 4.1.3. 
 
4.7.3 cDNA synthesis 
 
To amplify RNA in PCR, first it had to be reversely transcribed into DNA. 
Therefore, total cellular RNA was isolated from eukaryotic cells as described in 
materials and methods, 4.1.14. To exclude amplification of any residual DNA 
co-purified during RNA isolation, a DNAse digest was performed prior to cDNA 
synthesis as described in materials and methods, 4.7.4. The DNA-free solution 
was then used to reversely transcribe RNA into complementary DNA (cDNA), 
which subsequently could be amplified by PCR for further analysis. For 
reverse transcription (RT) the high-capacity cDNA reverse transcription kit 
(Applied Biosystems) was used. 
 
cDNA master mix :  2 µl  10 x RT buffer 
  0.8 µl  25 x dNTP mix (100 mM) 
  2 µl   10 x RT random Primers 
  1 µl  reverse transcriptase from  
    Moloney murine leukemia virus 
    (MoMuLV) 
  4.2 µl  nuclease-free H2O 
  10 µl  RNA template up to 2 µg 
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To perform reverse transcription of RNA, the following programme was used 
for amplification in a thermal cycler (step 1, primer annealing; step 2, reverse 
transcription; step 3, RT inactivation; step 4, storage): 
 
Profile step 1 step 2 step 3 step 4 
Temp 25°C 37°C 85°C 4 
Time 10 min 120 min 5 sec hold 
 
After synthesis of cDNA an aliquot of 1 µl was taken and subjected to PCR 
(see materials and methods 4.7.2). As a control, a PCR was performed using 
non reversely transcribed RNA as a template. The amplified product was 
analysed by agarose gel electrophoresis from both fractions. 
 
4.7.4 DNAse digest 
 
Prior to performing cDNA synthesis with the isolated RNA, a DNAse digest 
had to be performed, to remove traces of plasmid DNA remaining from 
previous transfections. In subsequent PCR amplifications presence of plasmid 
DNA would lead to a false positive signal. As a control for successful 
digestion, a PCR was performed before and after the digest. In order to 
exclude any DNA contamination, a double digest was performed using the 
TURBO DNA-free kit (Applied Biosystems). Up to 0.2 µg DNA/µl were treated 
in a rigorous DNAse digest. Digests were typically carried out in a reaction 
volume of 25 µl. 2.4 µl of 10 x TURBO DNAse buffer and 1 µl of TURBO 
DNAse were added to the RNA and incubated at 37°C. After 30 min, again 1 
µl of TURBO DNAse was added and the reaction incubated for further 30 min 
at 37°C. To stop the digest, 2.6 µl of DNAse inactivation reagent included in 
the kit, were added and mixed constantly during incubation for 5 min at room 
temperature. The inactivation reagent was separated by centrifugation at 
10000 x g for 1.5 min. The supernatant was carefully transferred to a new tube 
without touching the pelleted inactivation reagent which interferes with Taq 
DNA polymerase in subsequent PCR steps.  
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4.7.5 Semi-quantitative RT-PCR 
 
The semi-quantitative RT-PCR is a method for determining the in vivo 
expression level of recombinant SRS-RNA transcribed from the respective 
transfected expression vector. By comparing the signal strength generated by 
amplification of the cDNA in RT-PCR to a standard of reverse transcribed 
RNA of known amounts (in vitro transcribed SRS-RNA) the transcription level 
can be calculated. To this aim, RNA isolated out of transfected cells was 
reversely transcribed (see materials and methods 4.7.3) after rigorous DNAse 
treatment (see materials and methods 4.7.4) and subjected to semi-
quantitative PCR. A routine 30 cycle PCR amplification as described in 
materials and methods 4.7.3, was performed and tubes were removed from 
the thermocycler every three cycles and analysed on a 1% agarose gel. The 
signals obtained were compared to those of the standard allowing calculation 
of the respective cellular RNA expression level. 
 
4.8 Mass spectrometry 
 
In the present work RNA-binding proteins obtained from purification with the in 
vivo StreptoTag method were further analysed by mass spectrometry. 
Therefore, proteins were subjected to SDS-PAGE, the gel stained with AgNO3 
(see materials and methods 4.6.4) and the band of interest excised for 
submission to mass spectrometry. In this work, mass spectrometrical analysis 
was carried out by VetOMICS, a spin off company of the university of 
veterinary medicine Vienna. In MALDI (Matrix Assisted Laser 
Desorption/Ionisation) protein ions are generated by a laser beam. In an 
electrical field these ions are accelerated and sent through a flight tube with 
the lightest being the fastest and arriving at the detector first. The resulting 
time of flight (TOF) of the ionized peptide is proportional to its mass/charge 
ratio. For identification of the peptide corresponding protein, the spectrum can 
be blasted against a database of a given organism. 
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5. Results 
 
5.1 Affinity purification of recombinant proteins 
 
5.1.1 Purification of recombinant His-tagged HIV-1 Rev protein 
 
To establish the StreptoTag method for in vivo applications, a stepwise 
approach was chosen. In the first step recombinant HIV-1 Rev protein was 
purified by binding to in vitro transcribed SRS-RNA. Second, HIV-1 Rev was 
cellularly expressed but still isolated by using in vitro transcribed SRS-RNA. 
Finally, protein as well as RNA were expressed in co-transfected cells and 
directly applied to the column for purification. 
In the first step, purification conditions should be standardised using in vitro 
transcribed RNA (see materials and methods 4.1.15) in combination with 
functional recombinantly produced RNA-binding protein. As a model system, 
the well known RNA-protein interaction of HIV-1 Rev and its responsive 
element RRE was applied. Recombinant Rev protein was purified from E.coli 
transformed with the vector pETsRevCHis (see appendix 8.2) encoding the 
HIV-1 Rev protein C-terminally tagged with histidine. His-tagged protein was 
expressed and affinity purified by Ni-chelate chromatography as described in 
materials and methods, 4.2.4. Aliquots of FPLC-purified His-Rev protein were 
separated by SDS-PAGE and recombinant protein detected by Western 
blotting using a sheep α-Rev antibody diluted 1:4500 (Fitzgerald) as a 
primary, and a mouse anti-sheep antibody conjugated to horseradish 
peroxidase (HRP) as a secondary antibody (diluted 1:1300; DAKO); (Figure 
5.1.1). 
 
                                                                                                                Results 
 53 
 
 
Figure 5.1.1 Western blot of FPLC-purified recombinant HIV-1 RevCHis. Lane 1 : total 
protein extracts of E.coli harbouring pETsRevCHis prior to induction. Lane 2 : total protein 
extracts of E.coli harbouring pETsRevCHis 3 hours after induction with 1 mM IPTG. Lane 3 - 
Lane 13 : Aliquots of proteins of FPLC fractions 1 - 24. Lane 14 : empty. Lane 15 : 0.5 µg 
recombinant RevCHis from a previous purification (positive control). 
 
As shown in Figure 5.1.1, induction of expression of recombinant RevCHis 
protein was successfully achieved by addition of 1 mM IPTG (compare lane 1 
and lane 2). Analysis of the different fractions of the respective FPLC-
purification revealed recombinant protein in fractions 8 - 16 (Figure 5.1.1, lane 
6 - 10). Fractions 8 - 16 containing RevCHis were concentrated by size 
exclusion centrifugation units (Vivaspin) as described in materials and 
methods, 4.5.3. Purified RevCHis protein in size (14 kDa) was identical to a 
previously purified aliquot (0.5 µg) used as a positive control (Figure 5.1.1, 
lane 15). 
 
5.1.2 Purification of recombinant His-tagged MMTV Rem(p14) protein 
 
As a second model system for specific RNA-protein interactions, the MMTV 
Rem/RmRE system was investigated. Therefore, the RmRE binding part of 
MMTV Rem, the Rem(p14) protein was recombinantly expressed by E.coli 
containing the pETRemSPCHis vector (see appendix 8.2). His-tagged 
Rem(p14) was purified applying the same protocol as for affinity purification of 
HIV-1 RevCHis (see results 5.1.1). Aliquots of fractions eluted from FPLC 
were analysed by SDS-PAGE and Rem(p14) detected by Western blotting 
using a monoclonal mouse α-Rem antibody (M66; Hochman, Park et al. 1990) 
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as a primary and a rabbit α-mouse antibody conjugated to HRP (diluted 
1:10000) as a secondary antibody (Figure 5.1.2). The smaller band in lane 14 
most probably is degraded Rem(p14) protein due to long term storage. 
 
 
Figure 5.1.2 Western blot of FPLC-purified recombinant MMTV Rem(p14). Lane 1 : total 
protein extracts of E.coli harbouring pETRemSPCHis prior to induction. Lane 2 : total protein 
extracts of E.coli harbouring pETRemSPCHis 3 hours after induction with 1 mM IPTG. Lane 3 
- Lane 13 : Aliquots of proteins of FPLC fractions 1 - 24. Lane 14 : 0.5 µg recombinant 
Rem(p14)CHis from a previous purification (positive control). Lane 15 : 0.5 µg recombinant 
Rem(p14)CHis after concentration of FPLC fractions 3 - 9. 
 
As shown in Figure 5.1.2, induction of expression of recombinant 
Rem(p14)CHis protein was successfully achieved by addition of 1 mM IPTG 
(compare lane 1 and lane 2). Analysis of the different fractions of the 
respective FPLC-purification revealed recombinant protein in fractions 4 - 8 
(Figure 5.1.2, lane 4 - 6). Fractions 4 - 8 containing Rem(p14)CHis were 
concentrated by size exclusion centrifugation units (Vivaspin) as described in 
materials and methods, 4.5.3. Purified Rem(p14)CHis protein in size (19 kDa) 
was identical to a previously purified aliquot (0.5 µg) used as a positive control 
(Figure 5.1.2, lane 14). 
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5.2 In vitro transcription of Strepto-tagged RNA 
 
5.2.1 Synthesis of double Strepto-tagged HIV-1 RRE-RNA 
 
To retain recombinantly purified RevCHis protein on streptomycin-coupled 
sepharose columns, presence of its target RRE-RNA is essential. To facilitate 
binding of RRE-RNA to streptomycin, it was modified to contain a StreptoTag 
aptamer at the 5’ end as well as at the 3’ end (see introduction 3.2.2). The 
SRS-RNA was transcribed in vitro from the pTZSRS vector (see appendix 
8.2) linearised with EcoR1 starting from the T7 promoter resulting in a 350 
nucleotide long run-off transcript (see materials and methods 4.1.15). The 
transcribed RNA was analysed by denaturing agarose gel electrophoresis 
(see materials and methods 4.1.16) to verify molecule length and integrity. As 
depicted in Figure 5.2.2 lane 1, the in vitro transcription was successfully 
achieved. Full length SRS-RNA was obtained in sufficient quantities in the 
milligram range, and was used for subsequent affinity purification 
experiments. 
 
5.2.2 Synthesis of double Strepto-tagged MMTV RmRE-RNA 
 
For affinity column purification of recombinantly produced MMTV Rem(p14), 
successful in vitro transcription of its double Strepto-tagged Rem responsive 
element, the SRmS RNA, was a crucial point. Therefore, the pTZSRmS 
vector (see appendix 8.2) was linearised with EcoRI and subjected to in vitro 
transcription using the T7 polymerase (see materials and methods 4.1.15). 
The resulting product was analysed by denaturing agarose gel 
electrophoresis (see materials and methods 4.1.16). As shown in Figure 5.2.2 
lane 2, however, in contrast to SRS-RNA, only 10% of the synthesised 
SRmS-RNA appears to be full-length. This amount of 580 nt long full-length 
transcript was calculated to be insufficient to carry out column purification 
experiments. Although in vitro transcription was modified by increasing 
incubation time and decreasing incubation temperature, still full-length RNA 
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could not be produced to sufficient amounts. Similarly, trying different T7-
transcription systems such as the T7 RiboMAX Express Large Scale RNA 
production system (Promega), the TranscriptAid T7 High Yield Transcription 
Kit (Fermentas) as well as the In vitro transcription Kit (Roche), was not 
successful in producing full-length transcripts.  
 
Figure 5.2.2 Denaturing gel electrophoresis of in vitro transcribed SRS-RNA and 
SRmS-RNA. Lane 1 : 0.3 µg of double Strepto-tagged HIV-1 RRE-RNA (SRS) (expected 
size 350 nt). Lane 2 : 0.3 µg of double Strepto-tagged MMTV RmRE RNA (SRmS) (expected 
size 580 nt).  
 
5.3 In vivo transcription of Strepto-tagged viral target 
RNA 
 
5.3.1 In vivo transcription of SRS-RNA 
 
In the stepwise approach of establishing the StreptoTag method for in vivo 
applications, finally cells should be co-transfected with the SRS as well as the 
Rev encoding vector. For a successful isolation of Rev, full-length 
transcription of SRS-RNA in transfected cells was crucial and had to be 
demonstrated. Therefore, total cellular RNA extracted from 1.3x106 HEK293 
cells (one well of a 6-well plate), that had been transfected with 5 µg of the 
SRS encoding vector pCMVSRS (see appendix 8.2), was isolated (see 
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materials and methods 4.1.14), DNAse-treated (see materials and methods 
4.7.4) and reversebly transcribed (see materials and methods 4.7.3). PCR 
was performed (see materials and methods 4.7.2) using primers binding at 
the very ends of the 350 base pair long cDNA. Generation of the respective 
DNA fragment would indicate synthesis of the full-length SRS transcript. As a 
forward primer, the oligonucleotide 5’ - TAT ATC TAG ACA GTG GGA ATA 
GGA GCT TTG - 3’, and as a reverse primer, the oligonucleotide 5’ - AGG 
AGC TGT TGT CCT TTA GGT ATC - 3’ was used (primer pair A). The 
analysis was carried out in duplicates. The obtained PCR products were 
analysed by agarose gel electrophoresis. The results are shown in Figure 
5.3.2. Both PCR reactions (Figure 5.3.2, lane 4 and lane 5) gave rise to a 
product of 350 nt, corresponding to the full-length transcript of SRS-RNA. 
 
5.3.2 In vivo transcription of SRmS-RNA 
 
Similar to verification of in vivo full-length transcription of SRS-RNA (see 
results 5.3.1), analysis of transcription of double Strepto-tagged RmRE-RNA 
(SRmS) was performed. Therefore, cytoplasmic RNA was isolated from 
1.3x106 HEK293 cells transfected with 5 µg of pCMVSRmS (see appendix 
8.2). Since in vitro transcription of SRmS-RNA had mostly resulted in 
incomplete transcripts, it was of special interest if SRmS-RNA in vivo would 
be transcribed as a full-length transcript that will allow binding of Rem. 
Primers for PCR were selected to bind to the very ends of the 580 base pair 
long cDNA, thus only allowing amplification of reversely transcribed RNA if a 
full-length transcript has been produced. As a forward primer, the 
oligonucleotide 5’ - CGG ATC CGG AGT GAA GGC TTT AAA TC – 3’, and as 
a reverse primer the oligonucleotide 5’ – CAA ATG CGA TCC CTG TGG TCC 
TTG C – 3’  was used (primer pair B). Again, the analysis was carried out in 
duplicates. As seen in Figure 5.3.2, lane 2 and lane 3, reaction products were 
analysed by agarose gel electrophoresis. In contrast to in vitro transcribed 
SRmS-RNA, SRmS transcribed in vivo is a full-length molecule resulting in 
the expected fragment of 580 nucleotides in length. 
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Figure 5.3.2 Agarose gel electrophoresis of PCR fragments. Lane 1 : empty. Lane 2 and 
Lane 3 : PCR products obtained with reversely transcribed cellular SRmS-RNA. Lane 4 and 
Lane 5 : PCR products obtained with reversely transcribed cellular SRS-RNA. Lane 6 : no 
template control reaction. Lane 7 : 1 kb plus DNA Marker (Invitrogen). 
 
5.4 Determination of expression levels of cellular SRS- 
and SRmS-RNA 
 
In order to facilitate an efficient streptomycin-mediated affinity purification of 
viral RNA/protein complexes, both components had to be produced in 
sufficient amounts, in vitro as well as in vivo. Therefore, cellular SRS- as well 
as SRmS-RNA expression levels were investigated, applying a semi-
quantitative RT-PCR approach (see materials and methods 4.7.5). 100 µg of 
in vitro transcribed SRS-RNA were determined to be the required amount  to 
allow StreptoTag-mediated purification of recombinant RevCHis (Müllner 
Matthias, Diploma Thesis 2007). Therefore, cellular expression of SRS-RNA 
as well as SRmS-RNA in HEK293 cells transfected with pCMVSRS or 
pCMVSRmS (see appendix 8.2) should produce similar yields to facilitate 
successful isolation of cellular Rev. To ensure high expression levels of both, 
protein and target RNA, the transfection efficiency was of crucial importance. 
Therefore, transfection efficiencies were monitored by transfection of a 
reporter plasmid encoding green fluorescent protein, followed by quantitative 
evaluation using FACS (Figure 5.4.1, A-D). 
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Cells transfected with 1 µg of the reporter plasmid pCMVGFP (see appendix 
8.2) resulted in a transfection efficiency of 54.61% and cells transfected with 
10 µg of the reporter plasmid resulted in a transfection efficiency of 93.90%. 
According to these results, in all further experiments the reporter plasmid was 
co-transfected accounting for 10% of the total DNA amount, and only cells 
exhibiting a minimum transfection efficiency of 55% were further processed. 
 
  
A) B) 
 
  
C) D) 
 
Figure 5.4.1 A) Monitoring of transfection efficiencies : Cells transfected with 1 µg of the 
reporter plasmid pCMVEGFP show a transfection efficiency of 54.61%. B) Cells transfected 
with 10 µg of the reporter plasmid pCMVEGFP show a transfection efficiency of 93.90%. C) 
Cells co- transfected with pEGFPRev and pCMVSRS show a transfection efficiency of 
55.66%. D) Cells co-transfected with pEGFPRem and pCMVSRmS show a transfection 
efficiency of 63.99%. 
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Transfection efficiencies determined for plasmids encoding HIV-1 Rev, alone 
or as a fusion protein with EGFP, were shown to be in average about 10% 
lower compared to constructs coding for MMTV Rem, most probably due to 
cytotoxic effects. After successful transfection, cellular RNA was prepared and 
the amount of in vivo transcribed SRS- or SRmS-RNA was evaluated by 
applying semiquantitative RT-PCR (see materials and methods 4.7.5). 
As a standard for quantification of obtained RT-PCR products, in vitro 
transcribed SRS-RNA in amounts of 0.1 µg up to 0.7 µg was used (Figure 
5.4.2, panel G - panel J). By comparing the band intensities obtained after RT-
PCR of in vivo transcribed SRS- and SRmS-RNA with PCR products 
synthesised from the in vitro transcribed SRS-RNA standard, the respective 
amount of RNA was calculated. Quantification of cellular SRS and SRmS 
expression levels was carried out in duplicates, to improve calculation 
accuracy. The bands of in vivo transcribed SRS (Figure 5.4.2, panel E - lane 8 
and panel F - lane 8) and SRmS-RNA (Figure 5.4.2, panel C - lane 8 and 
panel D - lane 8) arising in cycle #30 correspond to the signal obtained with 
0.1 µg of standard RNA (Figure 5.4.2, panel J - lane 8). Corrected by the 
dilution factors in PCR (x 19), reverse transcription (x 10) and DNAse digest (x 
5) reactions, this amount equals a cellular expression level of 95 µg per 
1.3x106 cells. Thus, transcription of SRS- and SRmS-RNA from transfected 
expression vectors should provide a sufficient amount of RNA to facilitate 
isolation of the respective binding proteins in affinity chromatographic 
purifications.  
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Figure 5.4.2 Agarose gel electrophoresis of DNA fragments obtained from semi-
quantitative RT-PCR. Samples were taken every third cycle; a control lacking cDNA as a 
template was loaded in lane 9. Panels A and B : PCR products of reversely transcribed 
cellular RNA of non transfected cells. Panels C and D : PCR products obtained with 
reversely transcribed cellular RNA of cells transfected with pCMVSRmS. Panels E and F : 
PCR products obtained with reversely transcribed cellular RNA of cells transfected with 
pCMVSRS. Panel G : PCR products obtained with 0.7 µg reversely transcribed SRS-RNA 
standard. Panel H : PCR products obtained with 0.5 µg reversely transcribed SRS-RNA 
standard. Panel I : PCR products obtained with 0.3 µg reversely transcribed SRS-RNA 
standard. Panel J : PCR products obtained with 0.1 µg reversely transcribed SRS-RNA 
standard. 
 
                                                                                                                Results 
 62 
5.5 Step-wise adaption of StreptoTag-mediated affinity 
purification for in vivo application 
 
As mentioned previously, the final aim of this project is to establish the 
StreptoTag method for isolation of RNA-binding proteins in physiological 
conditions. Therefore, a stepwise approach from purely in vitro-derived 
components towards in vivo synthesised RNA and protein should be applied.  
 
 
Figure 5.5 Flowchart showing the step-wise approach for establishment of the 
StreptoTag-mediated affinity purification in vivo. 
 
As a first step, proof-of-principle for the StreptoTag method using in vitro 
transcribed SRS-RNA and recombinant Rev protein should be demonstrated. 
To this aim, 100 µg of in vitro transcribed double Strepto-tagged RRE (SRS) 
RNA was incubated with FPLC-purified recombinant His-tagged HIV-1 Rev 
protein and the complex loaded onto a streptomycin-coupled sepharose 
column (see results 5.5.1).  
As an intermediate step, recombinant Rev should be substituted by cellular 
Rev. Therefore, a crude extract of pCMVRev-transfected HEK293 cells was 
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incubated with in vitro-transcribed RNA and the mixture subjected to 
streptomycin-mediated affinity chromatography (see results 5.5.2).  
In the final approach, HEK293 cells should be co-transfected with the SRS-
RNA encoding vector and the Rev encoding vector. The RNA-protein 
interaction is then allowed to occur in vivo under biologically relevant 
conditions. Transfected cells were then subjected to native lysis and 
subsequently, in vivo formed Rev-SRS complexes should be successfully 
retained on the column (see results 5.5.3). Once this system is established it 
can be applied to shed light on novel RNA binding proteins under 
physiological conditions. 
 
5.5.1 Step #1 : Purification of recombinant Rev bound to in vitro transcribed 
SRS-RNA 
 
The first step in establishment of the StreptoTag method for in vivo application 
was to proof the principle of this idea with in vitro synthesised components. To 
this aim, in vitro transcribed SRS-RNA was used to retain recombinant Rev on 
a streptomycin-coupled sepharose column. Prior to incubation with Rev, 100 
µg in vitro transcribed SRS-RNA were refolded by incubation at 65°C, 
followed by incubation at 37°C and finally at room temperature for 8 min each. 
3 µg of FPLC-purified recombinant RevCHis protein were added, incubated at 
room temperature for 15 min and diluted in 4 ml of column buffer. The solution 
was loaded onto the column as described in materials and methods, 4.5.2. 
Rev protein bound to SRS-RNA should be retained on the column by affinity 
binding of the StreptoTag to streptomycin, coupled to the sepharose resin. 
Upon addition of 1 mM streptomycin, the Rev/SRS complex should be eluted 
and Rev protein be present in the in the respective fraction. The flow-through, 
five consecutive washing fractions and eluted protein were collected and 
precipitated by addition of acetone (see materials and methods 4.5.3). The 
precipitate was dissolved in 1 x protein sample buffer and separated by SDS-
PAGE followed by Western blot analysis. Rev was detected using a sheep α-
Rev antibody followed by incubation with a mouse anti-sheep secondary 
antibody conjugated to HRP. The majority of Rev was detected in the flow-
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through (Figure 5.5.3, panel A - lane 1) as 3 µg of protein is most probably 
exceeding the available binding sites on the SRS-RNA. Only the first (Figure 
5.5.3, panel A - lane 2) of the five washing steps contained Rev, indicating the 
strong interaction of protein and SRS-RNA as well as SRS-RNA and column 
material. Upon addition of 1 mM streptomycin, Rev was successfully eluted 
and could be detected in the elution fraction (Figure 5.5.3, panel A - lane 7). 
As a positive control, 0.5 µg of pure recombinant Rev protein was also 
subjected to analysis and shown to correspond in signal and molecular weight 
to the respective protein contained in the elution fraction. The difference 
between the calculated molecular weight of Rev, which is 13 kDa, and the 
detected molecular weight of 17 kDa is consistent with that of other proteins 
rich in basic amino acid residues (Nalin, Purcell et al. 1990). To monitor 
efficacy of precipitation of protein contained in FPLC-fractions, 3 µg of 
recombinant RevCHis were co-precipitated in each purification experiment 
(Figure 5.5.3, panel A - lane 9). Here, this signal is hardly visible due to signal 
interference with recombinant Rev in lane 10. 
 
5.5.2 Step #2 : Purification of cellular Rev bound to in vitro transcribed SRS-
RNA 
 
As a second, intermediate step in establishment of the StreptoTag method for 
in vivo applications, cellular Rev expressed as a EGFP-Rev fusion protein 
was isolated by StreptoTag affinity purification using in vitro transcribed SRS-
RNA. Expression of Rev protein as a fusion with green fluorescent protein 
was inevitable due to failure of all antibodies tested to recognise cellular HIV-1 
Rev protein (data not shown). Antibodies tested included three different lots of 
polyclonal sheep α-Rev antibody (Fitzgerald) as well as two monoclonal 
mouse α-Rev antibodies (# 3058 and # 3060) obtained from NIBSC UNaids. 
For the purification approach 107 HEK293 cells in a 10 cm dish were 
transfected with 25 µg of the EGFP-Rev encoding vector pEGFPRev (see 
appendix 8.2) and proteins were isolated after 48 hours by native cell 
fractionation to ensure a maximum yield of RNA-bound protein (see materials 
and methods 4.3.6). Nuclear and cytoplasmic fractions were unified and 
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incubated with 100 µg of refolded in vitro-transcribed SRS-RNA for 15 min at 
room temperature, followed by a stepwise loading of the complexes onto the 
column (see materials and methods 4.5.2). If cellularly expressed EGFP-Rev 
would bind to in vitro-transcribed SRS-RNA, it was expected to be retained on 
the column. Elution of the Rev/SRS complexes, protein concentration and 
SDS-PAGE of fractionated proteins was performed exactly as described in 
step #1 (see results 5.5.1). EGFP-Rev was detected in different fractions 
using a mouse α-EGFP antibody as a primary, and a rabbit α-mouse antibody 
conjugated to HRP as a secondary antibody. In contrast to the previous 
approach with recombinant Rev protein (see results 5.5.1), 100 µg of in vitro 
transcribed SRS-RNA seem to be sufficient to retain all cellularly expressed 
EGFP-Rev proteins on the column as no signal is obtained in the flow-through  
(Figure 5.5.3, panel B - lane 1) and washing step 1 fractions (Figure 5.5.3, 
panel B - lane 2). However, the interaction of in vivo synthesized EGFP-Rev 
with in vitro transcribed SRS-RNA seems to be weaker than with recombinant 
RevCHis, as some EGFP-Rev protein appears to be eluted during washing 
steps 2 - 4 (Figure 5.5.3, panel B - lanes 3 - 5). This may be due to the fusion 
of Rev to EGFP, which increases molecular weight and might reduce affinity 
of Rev to its target RNA. Nevertheless, the majority of the fusion protein was 
eluted upon addition of 1 mM streptomycin and could be detected in the 
elution fraction (Figure 5.5.3, panel B - lane 7). Recombinant RevCHis used 
as a positive control as well as the precipitated recombinant Rev protein 
(Figure 5.5.3, panel B - lanes 9 and 10) was not detected, as an α-EGFP 
antibody was used. 
 
5.5.3 Step #3 : Purification of cellular Rev bound to in vivo transcribed SRS-
RNA 
 
Having successfully shown that the principle of the StreptoTag method works 
for in vitro-derived components (Figure 5.5.3, panel A), and having isolated 
EGFP-Rev fusion protein from crude cell extracts in the intermediate step 
(Figure 5.5.3, panel B), the final approach was to apply the StreptoTag 
method for purification of in vivo-derived components. To this aim, EGFP-Rev 
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should be isolated from cells co-transfected with the protein and the SRS-
RNA encoding vectors. Therefore, 107 HEK293 cells in a 10 cm dish were 
transfected with the plasmids pCMVSRS and pEGFPRev in a ratio of 3 : 1. 
After 48 hours, nuclear and cytoplasmic proteins were isolated by native cell 
fractionation (see materials and methods 4.3.6), unified and stepwise loaded 
onto the column as described in materials and methods, 4.5.2. Here, the 
protein-RNA interaction was allowed to occur under physiological conditions 
within the cell. The Rev/SRS complex established in the cellular environment 
was expected to be retained on the column by affinity binding of the 
StreptoTag to the streptomycin-coupled sepharose resin. Elution of the 
Rev/SRS complexes, protein concentration and SDS-PAGE of fractionated 
samples was performed exactly as described in step #1 (see results 5.5.1). 
Again, EGFP-Rev was detected in different fractions using a mouse α-EGFP 
antibody as a primary, and a rabbit α-mouse antibody conjugated to HRP as a 
secondary antibody. As in 5.5.3, no EGFP-Rev was found in the flow-through 
(Figure 5.5.3, panel C - lane 1) and washing step 1 fractions (Figure 5.5.3, 
panel C - lane 2). In the washing steps 2 - 4 (Figure 5.5.3, panel C - lanes 3 - 
5) decreasing amounts of EGFP-Rev protein was found and finally no more 
protein was detected in the last washing fraction (Figure 5.5.3, panel C - lane 
6). The majority of EGFP-Rev was successfully eluted and detected in the 
elution fraction (Figure 5.5.3, panel C - lane 7). As in 5.5.2, recombinant 
RevCHis protein used as a positive control as well as the precipitated 
recombinant Rev protein (Figure 5.5.3, panel C - lanes 9 - 10) was not 
detected, as an α-EGFP antibody was used. Hence, the establishment of the 
StreptoTag method in vivo was successfully shown, subsequently allowing 
investigations of protein-RNA interactions under physiological conditions.  
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Figure 5.5.3 Stepwise approach for establishment of the StreptoTag method in vivo. 
Panel A : Western blot : Purification of recombinant RevCHis using in vitro transcribed SRS-
RNA. Panel B : Western blot : Purification of cellular EGFP-Rev fusion protein using in vitro 
transcribed SRS-RNA. Panel C : Western blot : Purification of EGFP-Rev fusion protein from 
HEK293 cells co-transfected with the RNA and the protein encoding vector. Lane 1 : flow –
through. Lanes 2-6 : wash fractions. Lane 7 : eluted protein. Lane 8 : recombinant His-
tagged Rev protein. Lane 9 : acetone precipitated recombinant Rev protein. 
 
5.5.4 Step #4 : Purification of cellular proteins bound to in vivo transcribed-
SRS-RNA 
 
As the in vivo StreptoTag method is based on RNA-protein interactions in the 
cellular environment of HEK293 cells, non-specific interference might occur. 
Cellular proteins may interact with and bind to the transiently transcribed 
SRS-RNA and therefore block RRE binding sites for EGFP-Rev. This may 
result in insufficient binding of the specific protein and therefore might reduce 
amounts to levels beyond detection limits. To investigate the presence of 
interfering proteins, 107 HEK293 cells in a 10 cm dish were transfected with 
25 µg of the SRS-RNA encoding vector pCMVSRS only. After 48 hours, 
nuclear and cytoplasmic proteins were isolated by native cell fractionation 
(see materials and methods 4.3.6), unified and stepwise loaded onto the 
column as described in materials and methods, 4.5.2. The transfection of high 
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amounts of plasmid DNA and respectively presence of vast amounts of target 
RNA should allow binding of sufficient amounts of potentially interfering 
endogenous cellular proteins to be detected by silver staining of the 
respective protein gel. Any protein bound to the SRS-RNA is retained on the 
column, eluted upon addition of 1 mM streptomycin and should be found in 
the elution fraction. As in previous experiments, also the flow-through, the 
consecutive wash and elution fractions were collected and contained proteins 
precipitated (see materials and methods 4.5.3). The precipitate was dissolved 
in 1 x protein sample buffer and separated by SDS-PAGE. Silver staining of 
the gel was performed, as this sensitive method allows detection of even 
small amounts of any protein contained in the fraction. Regularly, the majority 
of cellular proteins was found in the flow-through (Figure 5.6.2, panel A - lane 
1). Decreasing amounts of proteins were washed from the column during 
washing steps 1 - 3 (Figure 5.6.2, panel A - lanes 2 - 4) and no protein was 
found in fractions of washing steps 4 - 5 (Figure 5.6.2, panel A - lanes 5 - 6). 
No protein of a size that equals that of EGFP-Rev was found in the elution 
fraction (Figure 5.6.2, panel A - lane 7). However, potentially interfering 
proteins of different sizes were detected in the elution fraction and further 
characterised by mass spectrometrical analysis (see results 5.7.1). 
 
5.6 Isolation of cellular MMTV Rem protein 
 
After successful establishment of the StreptoTag method for in vivo 
applications using the well known interaction of HIV-Rev and RRE, the 
method should be applied to investigate interaction of the MMTV Rem protein 
with its RNA-binding partner RmRE. As described previously (see results 
5.2.2), in vitro transcription of full-length SRmS-RNA was not possible. Thus, 
a stepwise establishment of the StreptoTag-mediated affinity purification as 
performed with HIV-1 Rev and RRE was not possible. Therefore, purification 
readily started with the in vivo setup.  
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5.6.1 Purification of cellular Rem bound to in vivo transcribed SRmS-RNA 
 
The established in vivo StreptoTag method should now be applied to 
investigate the interaction of MMTV Rem and its responsive element RmRE 
analogue to the HIV-1 Rev/RRE system. Due to insufficient resources of the 
α-Rem antibody (M66; Hochman, Park et al. 1990) Rem had to be expressed 
as EGFP-Rem fusion protein for further detection. EGFP-Rem should be 
isolated out of HEK293 cells co-transfected with the RNA and the protein 
encoding vector. Therefore 107 HEK293 cells in a 10 cm dish were 
transfected with the SRmS-RNA encoding vector pCMVSRmS and the EGFP-
Rem encoding vector pEGFPRem in a ratio of 3 : 1. After 48 hours, nuclear 
and cytoplasmic proteins were isolated by native cell fractionation (see 
materials and methods 4.3.6), unified and loaded stepwise onto the 
streptomycin-coupled sepharose column as described in materials and 
methods, 4.5.2. The known interaction of MMTV Rem and RmRE is utilized to 
bind the protein to the column, mediated by the double Strepto-tagged RmRE-
RNA and its affinity to the streptomycin-coupled sepharose. Addition of 1 mM 
streptomycin should result in elution of bound EGFP-Rem protein. The flow-
through, the five consecutive washing fractions and the elution fraction were 
collected and contained protein precipitated with acetone (see materials and 
methods 4.5.3). The precipitate was dissolved in 1x protein sample buffer and 
separated by SDS-PAGE. EGFP-Rem was detected using a mouse α-EGFP 
antibody (1:1000 - Clontech) as a primary, and a rabbit α-mouse antibody 
conjugated to HRP as a secondary antibody (1:10000 - DAKO). In contrast to 
the HIV-1 Rev/RRE system, here EGFP-Rem was exclusively detected in the 
flow-through (Figure 5.6.1, panels A and B - lane 1) and the first wash fraction 
(Figure 5.6.1, panels A and B - lane 2). EGFP-Rem was neither detected in 
the consecutive washing fractions 2 - 5 (Figure 5.6.1, panels A and B - lanes 
3 - 6) nor in the elution fraction (Figure 5.6.1, panels A and B - lane 7). As 
seen from the multiple bands detected in the flow-through fraction, EGFP-
Rem appears to be processed either within cells or during preparation of 
protein extracts. Overall, full-length EGFP-Rem with the calculated size of 68 
kDa (EGFP 29 kDa plus Rem 39 kDa) could not be detected. In contrast, the 
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proteolytically cleaved EGFP-Rem(p14) (molecular weight 43 kDa), which is 
interacting with SRmS-RNA was found in the flow-through fraction (Figure 
5.6.1, panels A and B - lane 1) and the first wash fraction (Figure 5.6.1, 
panels A and B - lane 2). Two smaller cleavage products of 36 kDa and 30 
kDa, respectively, were additionally detected in these fractions (Figure 5.6.1, 
panels  A and B - lane 1). This result was confirmed by SDS-PAGE of the 
obtained fractions followed by silver-staining of the respective gel. Again, no 
protein was detected in the elution fraction (Figure 5.6.1, panel C – lane 7) 
 
 
Figure 5.6.1 Approach to isolate MMTV Rem protein applying the StreptoTag method in 
vivo. Panels A and B : Western blot : Affinity purification of cellular EGFP-Rem protein using 
in vivo transcribed SRmS-RNA. Panel C : Silver stain : AgNO3-stained SDS-PAGE of protein 
fractions obtained during purification of cellular EGFP-Rem with in vivo transcribed SRmS-
RNA. 
 
5.6.2 Purification of cellular proteins bound to in vivo transcribed SRmS-RNA 
 
After StreptoTag-mediated affinity purification of cellular EGFP-Rem was not 
successful, the next step was to determine if endogenously cellular proteins 
may interact with and bind to the transiently transcribed SRmS-RNA and 
therefore block RmRE binding sites for EGFP-Rem.  
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Consequently, levels of SRmS-RNA bound EGFP-Rem(p14) will decrease by 
lack of sufficient free binding sites and the level of EGFP-Rem(p14) 
necessary for immunodetection will not be reached. To investigate, if this 
might have occured, 107 HEK293 cells in a 10 cm dish were transfected with 
25 µg of the SRmS-RNA encoding vector pCMVSRmS only. After 48 hours, 
nuclear and cytoplasmic proteins were isolated by a native cell fractionation 
(see materials and methods 4.3.6), unified and stepwise loaded onto the 
streptomycin-coupled sepharose column (see materials and methods 4.5.2). 
This should allow binding of sufficient amounts of interfering endogenous 
cellular proteins to be detected by silver staining. Any protein bound to the 
SRmS-RNA is retained on the column, eluted upon addition of 1 mM 
streptomycin and precipitated from the elution fraction. The flow-through, the 
five consecutive washing fractions and the elution fraction were collected and 
precipitated with acetone (see materials and methods 4.5.3). The precipitate 
was dissolved in 1x protein sample buffer and separated by SDS-PAGE. 
Silver staining of the gel was performed, as this sensitive method allows 
detection of any protein in the fraction. The majority of cellular proteins was 
found in the flow-through (Figure 5.6.2, panel B - lane 1). Decreasingly 
amounts of proteins were washed away in washing steps 1 - 3 (Figure 5.6.2, 
panel B - lanes 2 - 4) and no protein was detected in washing steps 4 - 5 
(Figure 5.6.2, panel B - lanes 5 - 6). No protein of a size that equals that of 
EGFP-Rem(p14) is found in the elution fraction (Figure 5.6.2, panel B - lane 
7). Potentially interfering proteins of different sizes which were binding to the 
SRmS-RNA, however, were further characterized by mass spectrometrical 
analysis (see results 5.7.1). 
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Figure 5.6.2 Isolation of endogenous SRS/SRmS binding proteins by application of the 
StreptoTag method in vivo. Panel A - lane 7 : Affinity purification of HEK293 cells 
transfected with the SRS encoding vector only. Bands in the elution fraction marked in red 
were cut out and analyzed by mass spectrometry. Upper band was identified as human 
glutathione S-transferase and lower band as human dCTP pyrophosphatase 1. Panel B - 
lane 7 : Affinity purification of HEK293 cells transfected with the SRmS encoding vector only. 
Bands in the elution fraction marked in red were cut out and analyzed by mass spectrometry. 
As in panel B the upper band was identified as human glutathione S-transferase and the 
lower band as human dCTP pyrophosphatase 1. 
 
5.6.3 Evaluation of functional MMTV Rem/SRmS interaction in vivo 
 
Using the StreptoTag method it was not possible to show interaction of Rem 
protein with the double Strepto-tagged Rem responsive element, the SRmS-
RNA. This result might suggest that the Strepto-tags interfere with formation 
of the secondary structure of the RmRE-RNA. To show, that the 5’ and 3’ 
Strepto-tags within the SRmS do not impair binding of Rem, a heterologous 
HIV-1 gag RNA export assay was performed. 
Here, the HIV-1 Gag (see introduction 3.3.1) is expressed under the control of 
a pCMV promoter. No elements for the export of gag mRNA are included, 
resulting in its retention in the nucleus. By introducing an export element such 
as the constitutive transport element (CTE) of Mason-Pfizer monkey virus 
(MPMV), (Pasquinelli, Ernst et al. 1997; Saavedra, Felber et al. 1997; Yoon, 
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Lee et al. 1997), downstream of the gag encoding region, the RNA can be 
recovered and exported by the cellular export machinery (Gruter, Tabernero 
et al. 1998; Braun, Rohrbach et al. 1999; Bachi, Braun et al. 2000; Jin, Guzik 
et al. 2003). In contrast, for promoting export of RmRE containing RNA, co-
expression of the functional export protein is required. In this system, efficacy 
of the respective RNA export can be measured by the amount of cytoplasmic 
HIV p24 Gag protein produced applying Western blotting. 
To demonstrate functional interaction of Rem(p14) and its corresponding 
target sequence the RmRE (p3cRmRE) as well as the Strepto-tagged version 
SRmS (p3cSRmS) was inserted into the HIV-gag expression construct 
(Figure 5.6.3.1). As a control, the original HIV-Rev/RRE system was also 
investigated (p3cRRE). In addition, a construct harbouring the constitutive 
acting CTE of MPMV was analysed (p3cCTE). A construct lacking any 
transport element (p3cMCS) served as a negative control.  
For analysis, 1.2x106 CrFK cells in one well of a 6-well were transfected with 
the maximum of 5 µg vector DNA using Lipofectamine 2000 (Invitrogen), (see 
materials and methods 4.3.5). In co-transfections, the RNA and protein 
encoding vectors contributed in a ratio of 2 : 1 to the total DNA amount. 48 
hours after transfection, cell extracts were prepared and subjected to Western 
blot analysis. For immunodetection of HIV p24 Gag protein, a monoclonal α-
HIV p24 antibody (Polymun) was used. 
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Figure 5.6.3.1 Schematic representation of HIV p24 gag expression constructs used for 
analysis of functional Rem/RmRE interaction. p3c : back-bone vector; CMV : promoter of 
human Cytomegalovirus; HIV-1 gag/pro : RNA encoding p24 gag lacking RNA transport 
elements; HIV-1 Rev : HIV-Rev expression vector; MMTV Rem : regulator of export of MMTV 
mRNA; MCS : multiple cloning site; CTE : constitutive  transport element of Mason-Pfizer 
monkey virus; RRE : HIV-1 Rev responsive element; RmRE : MMTV Rem responsive 
element; SRmS : double Strepto-tagged MMTV Rem responsive element; pA : poly 
adenylation signal. 
 
The respective Western blot revealed, that gag mRNA not carrying an export 
element (p3c-MCS) was retained in the nucleus, hence no p24 Gag protein 
was detected (Figure 5.6.3.2, lane 2).  
Insertion of three copies of an MPMV CTE downstream of the Gag encoding 
region (p3c-CTE) resulted in recognition and export of the gag-mRNA via a 
general export pathway (Figure 5.6.3.2, lane 3). The HIV gag-mRNA is 
processed and p24 Gag protein detected, proofing functional interaction of the 
CTE export sequence and the corresponding cellular mediator of export. 
Replacing the CTE with the HIV RRE as an export element (p3c-RRE) 
required co-expression of HIV Rev protein, provided by co-transfection of 
pCMV-Rev (Figure 5.6.3.1). Functional interaction of Rev and its transport 
element was demonstrated by detection of a robust amount of p24 Gag 
protein (Figure 5.6.3.2, lane 5). 
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In contrast, expression of the RRE-containing Gag encoding vector only 
resulted in retention of the gag-mRNA in the nucleus, thus no p24 was 
produced (Figure 5.6.3.2, lane 4). Similarly, no Gag protein was detected 
when extracts of cells were analysed which had been transfected with a 
construct carrying the MMTV RmRE. 
Expression of the RmRE-gag encoding vector only causes gag-mRNA to be 
retained in the nucleus, as the necessary mediator of export, MMTV Rem, is 
not present (Figure 5.6.3.2, lane 6). Upon co-expression with Rem, the RmRE 
harbouring gag-mRNA is recognised by Rem and exported. Accordingly, p24 
Gag protein was detected (Figure 5.6.3.2, lane 7). 
Finally, the double Strepto-tagged MMTV RmRE, SRmS, was used as an 
export element. Without co-expression of the corresponding export protein, 
the gag-mRNA was retained in the nucleus (Figure 5.6.3.2, lane 8). Co-
expression of Rem resulted in export of gag-mRNA carrying the SRmS 
(Figure 5.6.3.2, lane 9), and production of the encoded p24 Gag protein to a 
similar extent as with constructs containing the wild-type sequence of RmRE 
(Figure 5.6.3.2, compare lanes 7 and 9). 
These results convincingly demonstrate that MMTV Rem protein is 
functionally expressed in transfected cells and interacts efficiently with its 
RNA target sequence, the original as well as the Strepto-tagged form. This 
indicates that the StreptoTag modification does not interfere with formation of 
RmRE secondary structure, which is essential for its recognition by Rem. 
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Figure 5.6.3.2 Heterologous HIV-1 gag export assay. Lane 1 : Marker. Lane 2 : Cell lysate 
of CrFK cells transfected with the HIV Gag encoding vector lacking a CTE. Lane 3 : Cell 
lysate of CrFK cells transfected with the HIV Gag encoding vector containing the MPMV CTE. 
Lane 4 : Cell lysate of CrFK cells transfected with the HIV Gag encoding vector containing 
the HIV-1 RRE. Lane 5 : Cell lysate of CrFK cells co-transfected with the HIV Gag encoding 
vector containing the HIV-1 RRE, and pCMV-Rev expression vector. Lane 6 : Cell lysate of 
CrFK cells transfected with the HIV Gag encoding vector containing the MMTV RmRE.  Lane 
7 : Cell lysate of CrFK cells co-transfected with the HIV Gag encoding vector containing the 
MMTV RmRE, and pCMV-Rem expression vector. Lane 8 : Cell lysate of CrFK cells 
transfected with the HIV Gag encoding vector containing the double Strepto-tagged MMTV 
RmRE. Lane 9 : Cell lysate of CrFK cells co-transfected with the HIV Gag encoding vector 
containing the double Strepto-tagged MMTV RmRE, and the pCMV-Rem encoding vector. 
Equal amounts of total protein were separated by SDS-PAGE and finally subjected to 
Western-blot analysis using a p24-Gag specific antibody. 
 
5.6.4 Evaluation of functional interaction of EGFP-Rem fusion protein and 
Strepto-tagged target RNA in vivo 
 
As pointed out previously, HIV-1 Rev as well as MMTV Rem are mediating 
the export of unspliced viral RNA from the nucleus to the cytoplasm. As 
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demonstrated before (see results 5.6.3), Rev as well as Rem functionally bind 
to the respective Strepto-tagged target sequence, thus facilitating export of 
HIV-gag RNA. However, in these experiments the natural viral proteins were 
investigated, while affinity-chromatographic purification has been performed 
with MMTV-EGFP-Rem fusion protein. The fluorescent activity of EGFP was 
utilised in the next experiment aiming at demonstrating functional protein/RNA 
interaction at the respective fusion protein in vivo. 
Therefore, CrFK cells were transfected in various combinations with fusion 
protein, RNA and mock encoding vectors (Figure 5.6.4.1 and Figure 5.6.4.2). 
Co-transfections with the RNA and protein encoding vectors were carried out 
in a plasmid ratio of 3 : 1. By transfecting the protein encoding vector only or 
the protein and mock encoding vectors, fluorescence was expected to be 
limited to the nucleus. Upon co-transfection of the protein encoding vector and 
the plasmid, encoding the responsive element bearing RNA, a shift of 
fluorescence from the nucleus to the cytoplasm should be observed. Visual 
analysis was carried out using a UV-fluorescence microscope with a specific 
filter detecting the green fluorescent protein (Axiovert 200 imaging system, 
ZEISS). 
For detection of EGFP-Rev/RRE interactions, 104 CrFK cells were transfected 
with 5 µg of vector DNA. Analysis by fluorescence microscopy was carried out 
48 hours post transfection. For comparison, cells were transfected with the 
EGFP-encoding vector pCMVEGFP only (Figure 5.6.4.1, panel A). In these 
cells, EGFP was shown to be equally distributed within the cytoplasm and the 
nucleus (Figure 5.6.4.1, panel A - lane 2). Cells that had been transfected with 
the EGFP-Rev encoding vector pEGFPRev (Figure 5.6.4.1, panel B), 
fluorescence was strictly limited to the nucleus (Figure 5.6.4.1, panel B - lane 
2). As Rev harbours an N-terminal nuclear localisation sequence (NLS), it is 
immediately translocated to the nucleus after translation at the endoplasmic 
reticulum (ER). In contrast, cells co-transfected with the EGFP-Rev encoding 
pEGFPRev and the RRE encoding vector p3C-RRE (Figure 5.6.4.1, panel C) 
show fluorescence only within the cytoplasm. Here, translocation occurs as 
EGFP-Rev located in the nucleus encounters RRE-harbouring RNA, binds to 
it and transports RNA to the cytoplasm, where it is consequently detected 
(Figure 5.6.4.1, panel C - lane 2). To investigate if the fusion protein would 
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also bind to double Strepto-tagged RRE, SRS, cells were co-transfected with 
the EGFP-Rev encoding pEGFPRev and the SRS encoding vector pCMVSRS 
(Figure 5.6.4.1, panel D). Exactly as in Figure 5.6.4.1 panel C, EGFP-Rev 
was detected exclusively in the cytoplasm (Figure 5.6.4.1, panel D - lane 2), 
demonstrating EGFP-Rev mediated RNA export, associated with protein 
translocation. The export of the EGFP-Rev/RNA complex occurs only if the 
RNA carries the responsive element. This was demonstrated in cells co-
transfected with the EGFP-Rev encoding vector pEGFPRev and a vector 
encoding for a mock RNA derived from pcDNA3.1 (Figure 5.6.4.1, panel E). 
Here, fluorescence was accordingly strictly limited to the nucleus (Figure 
5.6.4.1, panel E - lane 2) . 
Similar to this experimental setup, cells were also transfected with the 
corresponding plasmids allowing visual evaluation of EGFP-Rem and SRmS 
RNA interaction. 
As a control, cells were again transfected with the EGFP encoding vector 
pCMVEGFP only (Figure 5.6.4.2, panel A). Cells transfected with the EGFP-
Rem encoding vector pEGFPRem (Figure 5.6.4.2, panel B - lane 2) show a 
fluorescence strictly limited to the nucleus. In contrast to cells transfected with 
pEGFPRev (Figure 5.6.4.1, panel B - lane 2), here fluorescence is also visible 
in little dots surrounding the nucleus (Figure 5.6.4.2, panel B - lane 2). 
Identical to HIV-1 Rev, Rem harbours an N-terminal NLS, hence it is 
immediately translocated to the nucleus after translation at the endoplasmic 
reticulum. As no vector encoding for the RmRE was co-transfected, EGFP-
Rem remains in the nucleus and no translocation occurs. In contrast to the 
HIV-1 Rev/RRE system, where fluorescence is strictly limited to the cytoplasm 
upon co-transfection of EGFPRev and RRE/SRS encoding vectors (Figure 
5.6.4.1, panels C and D - lane 2), in cells expressing EGFP-Rem 
(pEGFPRem) and RmRE (p3CRmRE) a fluorescent shift to the cytoplasm is 
observed but still some protein is contained in the nucleus (Figure 5.6.4.2, 
panel C - lane 2). Co-transfection of vectors encoding EGFP-Rem 
(pEGFPRem) and the double Strepto-tagged RmRE, SRmS (pCMVSRmS), 
reveals the same fluorescence pattern (Figure 5.6.4.2, panel D - lane 2) as 
observed by co-transfecting the non-tagged RmRE (compare Figure 5.6.4.2, 
panel C - lane 2). In contrast, EGFP-Rem encoding vector (pEGFPRem) co-
                                                                                                                Results 
 79 
transfected with a vector encoding for a mock RNA (pCDNA3.1) as a control 
resulted in the same fluorescence pattern as transfection with pEGFPRem 
only (Figure 5.6.4.2, panel E - lane 2). Hence, as shown before (Figure 
5.6.3.2, lane 9) expression of the RmRE as double Strepto-tagged hybrid 
RNA does not impair the export mechanism. Moreover, functional interaction 
of both target RNAs with the EGFP-fusion protein was clearly demonstrated. 
In conclusion, it was demonstrated that MMTV Rem protein in its natural form 
as well as in fusion with green fluorescent protein functionally interacts with 
Strepto-tagged RNA and mediates RNA export as shown previously for the 
Rev/RRE system. 
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Figure 5.6.4.1 Fluorescence microscopy of CrFK cells transfected with : A) pCMVEGFP 
vector encoding green fluorescent protein. B) pEGFPRev vector encoding fusion protein 
EGFP-Rev. C) pEGFPRev and p3C-RRE vectors encoding fusion protein EGFP-Rev and 
RRE-RNA. D) pEGFPRev and pCMVSRS vectors encoding fusion protein EGFP-Rev and 
double Strepto-tagged RRE-RNA SRS. E) pEGFPRev and pcDNA3.1 vectors encoding 
fusion protein EGFP-Rev and mock RNA. Representative pictures of a culture with about 
40% transfected cells are shown. (Axiovert 200 imaging system, ZEISS; magnification 400x). 
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Figure 5.6.4.2 CrFK cells transfected with : A) pCMVEGFP vector encoding green 
fluorescent protein. B) pEGFPRem vector encoding fusion protein EGFP-Rem. C) 
pEGFPRem and p3CEnvLTR-Jun vectors encoding fusion protein EGFP-Rem and RmRE-
RNA. D) pEGFPRem and pCMVSRmS vectors encoding fusion protein EGFP-Rem and 
double Strepto-tagged RmRE-RNA SRmS. E) pEGFPRem and pcDNA3.1 vectors encoding 
fusion protein EGFP-Rem and mock RNA. Representative pictures of a culture with about 
40% transfected cells are shown. (Axiovert 200 imaging system, ZEISS; magnification 400x).  
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5.7 Isolation of novel RNA binding proteins 
 
Having shown with the Rev/RRE system that the StreptoTag method can be 
applied to isolate RNA-binding proteins from eukaryotic cells, a final approach 
was made to isolate novel putative RNA-binding proteins under physiological 
conditions.  
For isolation of novel RNA interacting proteins any putative target RNA 
sequence may be cloned and expressed as a double Strepto-tagged RNA 
hybrid. For identification of endogenous RNA-binding proteins, cells may then 
be transfected with this RNA encoding vector. Any Strepto-tagged RNA 
expressed within cells can be isolated with the potentially interacting protein 
bound and finally purified by affinity chromatography using a streptomycin-
coupled sepharose column. In this last approach, cells were transfected with 
SRS- or SRmS-RNA encoding vectors (Figure 5.7.1.1, panel B), respectively, 
followed by Strepto-Tag affinity chromatography and analysis of isolated 
proteins by mass spectrometry. 
 
5.7.1 Screening of HEK293 cells for protein interactions with SRS- and 
SRmS-RNA 
 
In this approach, HEK293 cells were transfected with either the SRS or the 
SRmS encoding vector. Interaction of endogenous, potentially RNA binding 
proteins was allowed to occur in the cellular environment. Complexes formed 
in vivo with novel binding partners were then purified via a streptomycin-
coupled sepharose column (see materials and methods 4.5.2) and isolated 
proteins identified by mass spectrometry (see materials and methods 4.8).  
In detail, 107 HEK293 cells in a 10 cm dish were transfected with 25 µg of 
either the SRS or the SRmS encoding vectors, pCMVSRS and pCMVSRmS, 
respectively. After 48 hours nuclear and cytoplasmic proteins were isolated by 
native cellular fractionation (see materials and methods 4.8.6), unified and 
stepwise loaded onto a column as described previously. The flow-through, the 
five washing fractions and the elution fractions were collected and protein 
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precipitated by addition of acetone (see materials and methods 4.5.3). The 
pellet was dissolved in 1 x protein sample buffer and separated by SDS-
PAGE. Silver staining of the gel, compatible with subsequent mass 
spectrometric analysis was performed. As shown in Figure 5.7.1.1, expressing 
either SRS- or SRmS-RNA, both led to the same results : two distinct proteins 
of a molecular weight of about 20 kDa and 25 kDa (red circles in Figure 
5.7.1.1, panels A and B) were purified. The purifications were carried out in 
duplicates, the respective protein-bands excised and pooled to increase the 
amounts subjected to mass spectrometrical analysis. Results identified the 
larger protein in the elution fraction to be human glutathione S-transferase 
with a molecular weight of 23.3 kDa (Figure 5.7.1.2) and the smaller protein to 
be human dCTP pyrophosphatase 1, with a molecular weight of 18.7 kDa 
(Figure 5.7.1.3). 
 
 
Figure 5.7.1.1 Isolation of endogenous SRS/SRmS binding proteins by application of 
the StreptoTag method in vivo. Panel A - lane 7 : Affinity purification of HEK293 cells 
transfected with the SRS encoding vector only. Bands in the elution fraction marked in red 
were cut out and analyzed by mass spectrometry. Panel B - lane 7 : Affinity purification of 
HEK293 cells transfected with the SRmS encoding vector only. Bands in the elution fraction 
marked in red were cut out and analysed by mass spectrometry. 
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Figure 5.7.1.2 Mass spectrometric analysis MALDI-TOF of pooled upper bands shown 
in Figure 5.7.1.1, panels A and B. The protein was identified as human glutathione S-
transferase P (MW 23.3 kDa) with a significant score of 161.5 whereupon the level of 
significance is 80.  
 
 
Figure 5.7.1.3 Mass spectrometric analysis MALDI-TOF of pooled lower bands in 
5.7.1.1, panels A and B. The signal was identified as human dCTP pyrophosphatase 1 (MW 
18.7 kDa) with a significant score of 235.9 whereupon the level of significance is 80. 
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6. Discussion 
 
Within the present work, the StreptoTag-mediated purification of RNA-binding 
proteins has been successfully established for in vivo applications. This 
provides an interesting new tool for investigating potential RNA-protein 
interactions under physiological conditions. In the course of its development, 
the StreptoTag method has been optimised, i.e. by modification of the RNA-
aptamer (Dangerfield, Windbichler et al. 2006) or addition of a second 
StreptoTag at the 5’ end of the target RNA (Müllner Matthias, Diploma Thesis 
2007). The adaption of the StreptoTag method from using only two simple in 
vitro components, namely the in vitro transcribed RNA and a recombinant 
protein, to the StreptoTag method in vivo, as presented in this work, also 
implied dealing with the many times more complex environment of the cell. In 
this regard, a step-wise approach for establishment of the method in vivo 
based on the HIV-1 Rev/RRE system was a necessary and successful 
approach. In contrast, the first application of the StreptoTag method in vivo, 
investigating the RNA-protein interaction of MMTV Rem and RmRE, was 
encountering obstacles in vitro as well as on the cellular level both of which 
could not be overcome so far. 
The step-wise approach for the establishment of the StreptoTag method in 
vivo, as performed for the HIV-1 Rev/RRE system, could not be transferred 
and applied to the MMTV Rem/RmRE system, as in vitro transcription of 
double Strepto-tagged RNA was impaired and resulted in incomplete 
transcripts. The reason for incomplete transcription may be due to the 
sequence of the SRmS (Figure 6.1). 200 nucleotides after transcription 
initiation at the T7 promoter, the T7 polymerase encounters a 12 base pair 
stretch of adenosines located within the RmRE, intercepted by only one 
guanine. The 12 adenosines are most likely weakening the 8 base pair DNA-
RNA formed by the T7 polymerase during RNA synthesis thereby inducing 
dissociation of the DNA-RNA-polymerase complex which results in incomplete 
transcripts. Nevertheless, RNA containing a wild-type MMTV RmRE (nt 1-
496) which also contains the adenosine rich sequence was previously 
successfully transcribed in vitro using the T7 polymerase (Mertz, Chadee et 
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al. 2009). In contrast, in vivo transcription by cellular polymerases was found 
to overcome this obstacle as shown by full-length RNA synthesized from 
transfected pCMVSRmS plasmid (Figure 5.4.2, panels C and D - lane 8). 
 
Figure 6.1 Partial sequence of the pTZSRmS encoding vector used for in vitro 
transcription of SRmS RNA. T7, promoter recognized by T7 polymerase; STag, 
StreptoTag; RmRE, MMTV Rem responsive element; LacZ, gene coding for enzyme β-
galactosidase. 
 
However, although target RNA in vivo has been synthesized, in contrast to 
purification of HIV-Rev, MMTV Rem(p14) could not be isolated from HEK293 
cells co-transfected with the Rem(p14) protein- and SRmS RNA-encoding 
vector (Figure 5.6.1). Rem had to be expressed as an EGFP fusion protein to 
facilitate detection due to insufficient resources of α-Rem antibody (M66). It 
was shown that EGFP- fusion neither with Rev nor with Rem inhibits RNA 
interaction in vivo (see results 5.6.4; and Stauber, Gaitanaris et al. 1995). 
Nevertheless, the multiple possibilities of interference on the cellular level e.g. 
protease-mediated degradation have to be considered when interaction of the 
Rem protein and the SRmS-RNA occurs under physiological conditions. As 
shown in Figure 5.6.1, application of the StreptoTag method in vivo for affinity 
purification of EGFP-Rem fusion protein did not result in isolation of any 
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specific binding protein present in the elution fraction. Instead, multiple 
proteins of different sizes ranging from 30 kDa to 43 kDa were found in the 
flow-through and wash 1 fraction. Full-length EGFP-Rem was not detected in 
any of the fractions in contrast to its cleavage product EGFP-Rem(p14). This 
indicates that proteolytical processing occurs within HEK293 cells cleaving 
EGFP-Rem (68 kDa) into EGFP-Rem(p14) (43 kDa) and gp32Rem, and into 
further fragments of 30 kDa and 36 kDa, respectively. This might reduce 
levels of EGFP-Rem and EGFP-Rem(p14) below detection limits in Western 
blot analysis using the α-EGFP antibody. Thus, at this point it is not possible 
to determine whether EGFP-Rem or EGFP-Rem(p14) might have bound to 
the Strepto-tagged RNA and subsequently were purified by affinity 
chromatography. 
Although proteolytic-cleavage might have been the main cause for a failure of 
detection, at this point also the second part of the purification system, the 
Strepto-tagged target RNA, SRmS was analysed for its integrity. 
The StreptoTag-mediated affinity purification was successfully established for 
the HIV-1 Rev/RRE system and EGFP-Rev was isolated from co-transfected 
HEK293 cells (see results 5.5.3). So far, the Strepto-tags added to the target 
RNA were not considered to impair the binding of the protein. This had to be 
verified also for the Rem/SRmS interaction. To show that the 5’ and 3’ 
Strepto-tags within the SRmS do not impair the binding of Rem, a 
heterologous HIV-1 gag RNA export assay was performed (see results 5.6.3). 
As shown in Figure 5.6.3.2 - lane 9, HIV-1 gag mRNA carrying the double 
Strepto-tagged MMTV RmRE is effectively exported by the co-expressed 
MMTV Rem protein and consequently p24 protein was expressed, indicating 
that the Strepto-tags did not impair formation of the RmRE secondary 
structure essential for its recognition by Rem. 
Additional to the cleavage of EGFP-Rem by endogenous peptidases, the 
specificity of the RNA-protein interaction of EGFP-Rem and SRmS in 
comparison to the highly specific EGFP-Rev and SRS interaction (Iwai, 
Pritchard et al. 1992; Mann, Mikaelian et al. 1994; Wang, Ma et al. 2010) 
might be considered as a factor decreasing detection probability of purified 
Rem in this approach. 
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A hint for only modest binding of Rem to its target RNA might be drawn from 
fluorescence microscopy data (Figure 5.6.4.2). Both proteins, Rev and Rem, 
carry an N-terminal NLS (Cullen, Hauber et al. 1988; Stauber, Gaitanaris et al. 
1995; Stauber, Afonina et al. 1998; Indik, Günzburg et al. 2005) which in 
absence of the respective RNA target sequence restricts the protein to the 
nucleus (Kalland, Szilvay et al. 1994; Richard, Iacampo et al. 1994; 
D'Agostino, Ciminale et al. 1995). Upon co-transfection of SRS, the vast 
amount of Rev translocated into the cytoplasm as shown by evenly distributed 
fluorescence sparing the nuclei (Figure 5.6.4.1, panel D - lane 2). This clear-
cut picture was not seen with MMTV Rem interacting with RmRE- or SRmS-
RNA. Here, only weak fluorescence was found in the cytoplasm and nuclei 
still appeared to contain substantial amounts of the EGFP-Rem fusion protein 
(Figure 5.6.4.2, panel D - lane 2). Thus, the less effective translocation 
observed here is in contrast to the interaction of EGFP-Rev and RRE/SRS, 
possibly indicating the reduced specificity of the MMTV Rem/RmRE 
interaction. 
Taking this into account, also interference of cellular proteins potentially 
binding to the SRmS target RNA might hinder effective isolation of Rem. In 
expression, besides the co-expressed protein of interest, target RNA within 
the cell may also be covered by many endogenous cellular proteins due to 
unspecific interactions which are thereby blocking free binding sites for the 
RNA-binding protein of interest. StreptoTag-mediated affinity purification of 
protein extracts derived from HEK293 cells transfected with the SRS- or 
SRmS-RNA encoding vector only resulted in purification of two unspecific 
interacting endogenous proteins. Further characterisation identified these 
proteins as human glutathione S-transferase P and  human dCTP 
pyrophosphatase 1  (Figure 5.7.1.1, panels A and B - lane 7).  
According to the ExPASy proteomics server (Swiss Institute of Bioinformatics) 
glutathione S-transferase (Mannervik, Alin et al. 1985; Kano, Sakai et al. 
1987) as well as dCTP pyrophosphatase do not carry any DNA/RNA binding 
motifs. However, as the same unspecific proteins were purified with both 
double Strepto-tagged RNA target sequences, the HIV-1 RRE as well as the 
MMTV RmRE (Figure 5.7.1.1, panels A and B - lane 7), which differ in 
sequence  as well as secondary structure, this unspecific binding might be 
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rather due to the presence of the Strepto-tag itself. This tags show the same 
secondary structure in both RNAs and therefore might bind proteins 
independent of the respective target sequence.  
The StreptoTag method in vivo, as presented in this work, was the first 
application of the StreptoTag affinity purification in a cellular environment and 
so far no other work has been published indicating a possible interaction of 
the StreptoTag RNA aptamer with cellular proteins. The low specificity of the 
system encountered during purification of Rem might however be overcome 
by applying less stringent conditions, such as increasing incubation by e.g. 
incubating the RNA-protein mixture with the sepharose over night. 
The problem of non-specific binding has also been described for other RNA 
aptamer affinity tags, such as those based on the interaction with streptavidin 
and dextran 512, both of which also allow elution of bound proteins under 
native conditions (Srisawat and Engelke 2001).  
Besides the incorporation of an artificially selected RNA motif, such as the 
StreptoTag (Bachler, Schroeder et al. 1999; Dangerfield, Windbichler et al. 
2006), Sephadex RNA motif and Streptavidin RNA motif (Srisawat and 
Engelke 2001; Srisawat, Goldstein et al. 2001), different alternative methods 
for tagging a specific RNA are available, all of them implying several 
obstacles.  
Thus, chemical tagging of RNA during in vitro transcription with e.g. biotin, 
fluorescent dyes or digoxeginin, leads to structural variations that can inhibit 
the formation of the RNA-protein complex (Rouault, Hentze et al. 1989). 
Moreover, as tagging of RNA is only applicable for in vitro studies, the 
complexes formed may not reflect those which could have built under native 
conditions.   
The incorporation of a well-characterised protein binding sequence into RNA 
during in vitro or in vivo transcription, which is applied for the system which is 
based on the interaction the MS2 coat protein and its cognate RNA (Bardwell 
and Wickens 1990), may result in inefficient elution of the purified complex, as 
this specific RNA-protein interaction is supposed to be very stringent (Das, 
Zhou et al. 2000). Alternatively, a protease cleavage site might be introduced 
to directly release the protein of interest from the column upon proteolytic 
processing (Leonov, Sergiev et al. 2003). Tagging of a specific RNA may also 
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be achieved by hybridisation with affinity-tagged biotinylated oligonucleotides. 
These are complementary to accessible single-stranded regions of the target 
RNA but have limited application in highly structured RNAs (Blencowe, Sproat 
et al. 1989; Walker, Scott et al. 2008). 
In summary, all of the methods described, imply their very own 
disadvantages. However, the StreptoTag method for in vivo applications, as 
established here, may nevertheless provide added value. First, the Strepto-
tags allow synthesis of even highly structured RNAs in vivo. This is 
particularly important as regulatory proteins often require formation of 
complex secondary structures to allow binding (Magin-Lachmann, Hahn et al. 
2001). Second, as no further modifications have to be made, the RNA-protein 
complex as established under physiological conditions can be readily loaded 
onto the affinity column and analysed under mostly native conditions. Finally, 
considering its limitations, the StreptoTag method should now facilitate to 
shed light on novel RNA-protein interactions as they occur in vivo.     
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8. Appendix 
 
8.1 Abbreviations 
 
x times 
x g times gravitational acceleration 
°C degree Celsius 
A adenine 
aa amino acid 
BSA bovines serum albumin 
bp base pair 
C cytosine 
cm2 square centimetre 
DEPC diethylpyrocarbonate 
dH2O distilled water 
ddH2O double distilled water 
DMEM Dulbeccos’s modified Eagle’s medium 
DMSO dimethyl sulfoxide 
DNA deoxyribonucleic acid 
dNTP  deoxyribonucleotid triphosphate 
DTT dithiothreitol 
EDTA ethylene-diamine- tetraacetate 
env envelope 
G guanine 
gag group specific antigen 
HIV human immunodeficiency virus 
hr hour 
HRP  horseradish peroxidase 
IPTG Isopropyl β-D-1-thiogalactopyranoside 
kb kilo bases 
kV kilo volts 
L litre 
LD loading dye 
LTR long terminal repeat 
M molar 
mA milliamp 
min minute 
ml millilitre 
mm millimetre 
mM millimolar 
MMTV Mouse mammary tumor virus 
MOPS 3-(N-morpholino)propanesulfonic acid 
mRNA messenger ribonucleic acid 
Nef negative factor 
NES nuclear export signal 
ng nanogram 
NLS nuclear localisation signal 
nm nanometre 
nM nanomolar 
nt nucleotide 
OD optical density 
O/N over night 
PBS phosphate buffered saline 
PCR polymerase chain reaction 
PMSF phenylmethanesulfonylfluoride 
pol polymerase 
PSB protein sample buffer 
Rem regulator of export of MMTV mRNA 
Rev regulator of the expression of the virion 
RNA ribonucleic acid 
rNTP ribonucleotid triphosphate 
rRNA robosomal ribonucleic acid 
RRE Rev responsive element 
RmRE Rem responsive element 
rt room temperature 
sec second 
Stag StreptoTag 
TEMED tetramethylethylenediamine 
Temp temperature 
tRNA transfer ribonucleic acid 
U  unit 
UTP uridine triphosphate 
UV ultra violet 
V volt 
v/v volume to volume ratio 
v/w volume to weight ratio 
wt wild type 
µg microgram 
µl micro litre 
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8.2 Plasmids 
pETRevCHis : IPTG-inducible procaryotic expression vector encoding C-
terminally histidine-tagged HIV-1 Rev protein. 
 
T7 : Promoter recognized by T7 polymerase; SD : Shine-Dalgarno-sequence recognized by 
procaryotic ribosomes and start of translation; sRevCHis : C-terminal histidine-tagged HIV-1 
Rev protein; Term : Termination signal recognized by bacterial ribosomes and end of 
translation; amp : β-lactamase encoding ampicillin resistance gene; ori : origin of replication 
 
pETRemSPCHis : IPTG-inducible procaryotic expression vector encoding C-
terminally histidine-tagged MMTV Rem protein. 
 
T7 : Promoter recognized by T7 polymerase; SD : Shine – Dalgarno – Sequence recognized 
by procaryotic ribosomes and start of translation; RemSP : 14 kDa cleavage product of full – 
length MMTV Rem protein; Term : Termination signal recognized by bacterial ribosomes and 
end of translation; amp : β-lactamase encoding ampicillin resistance gene; ori : origin of 
replication 
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pTZSRS : Vector for in vitro transcription of double Strepto-tagged HIV-1 
RRE-RNA. 
 
 
T7 : Promoter recognized by T7 polymerase; STag : StreptoTag; RRE : HIV-1 Rev 
responsive element; f1 (IG) : origin of replication of bacteriophage f1; amp : β-lactamase 
encoding ampicillin resistance gene; rep : origin of replication 
 
pTZSRmS : Vector for in vitro transcription of double Strepto-tagged MMTV 
RmRE-RNA. 
 
 
 
STagT : StreptoTag; RmRE : MMTV Rem responsive element; amp : β-lactamase encoding 
ampicillin resistance gene; rep : origin of replication 
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pCMVRev : Eucaryotic expression vector encoding HIV-1 Rev protein. 
 
  
 
hCMV : promoter of human Cytomegalovirus; sRev : HIV-1 Rev protein; amp : β-lactamase 
encoding ampicillin resistance gene; 
 
pCMVRemCHis : Eucaryotic expression vector encoding C-terminally 
histidine-tagged MMTV Rem protein. 
 
 
CMV : promoter of human Cytomegalovirus; MCS : Multiple cloning site; T7 : Promoter 
recognized by T7 polymerase; SP : 14 kDa cleavage product of full – length MMTV Rem 
protein; RemCHis : C-terminally histidine-tagged MMTV Rem protein; poly A : 
polyadenylation signal SV40 pr. : SV40 early promoter; SV40 ori : SV40 origin of replication; 
SV40 poly A : SV40 polyadenylation signal; amp : β-lactamase encoding ampicillin 
resistance gene; neo : Neomycin resistance gene 
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p3C-RRE : Eucaryotic expression vector encoding HIV-1 Rev responsive 
element RNA. 
 
P CMV : promoter of human Cytomegalovirus; T7 : Promoter recognized by T7 polymerase; 
gag : group - specific antigen; pol : polymerase; RRE : Rev responsive element; BGH pA : 
bovine growth hormone polyadenylation signal; P SV40 : SV40 early promoter; SV40 ori : 
SV40 origin of replication; SV40 poly A : SV40 polyadenylation signal; amp : β-lactamase 
encoding ampicillin resistance gene; neo : Neomycin resistance gene; ColE1 ori : origin of 
replication 
p3CRmRE : Eucaryotic expression vector encoding MMTV Rem responsive 
element RNA. 
 
P CMV : promoter of human Cytomegalovirus; T7 : Promoter recognized by T7 polymerase; 
gag : group - specific antigen; pol : polymerase; env : envelope; 3’ LTR : MMTV 3’ Long 
terminal repeat; BGH pA : bovine growth hormone polyadenylation signal; P SV40 : SV40 
early promoter; SV40 ori : SV40 origin of replication; SV40 poly A : SV40 polyadenylation 
signal; amp : β-lactamase encoding ampicillin resistance gene; neo : Neomycin resistance 
gene; ColE1 ori : origin of replication 
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pCMVSRS : Eucaryotic expression vector encoding double Strepto-tagged 
HIV-1 RRE-RNA. 
 
CMV : promoter of human Cytomegalovirus; T7 : Promoter recognized by T7 polymerase; 
STagT : StreptoTag; RRE : HIV-1 Rev responsive element; poly A : BGH polyadenylation 
signal; SV40 pr. : SV40 early promoter; SV40 ori : SV40 origin of replication; SV40 poly A : 
SV40 polyadenylation signal; amp : β-lactamase encoding ampicillin resistance gene; neo : 
Neomycin resistance gene; 
 
 
pCMVSRmS : Eucaryotic expression vector encoding double Strepto-tagged 
MMTV RmRE-RNA. 
 
 
hCMV : promoter of human Cytomegalovirus; STag : StreptoTag; RmRE : MMTV Rem 
responsive element; amp : β-lactamase encoding ampicillin resistance gene; 
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pEGFPRev : Eucaryotic expression vector encoding EGFP-tagged HIV-1 Rev 
fusion protein. 
 
 
P CMV : promoter of human Cytomegalovirus; eGFPRev : enhanced green fluorescent 
protein fused to HIV-1 Rev; kan/neo : kanamycin and neomycin resistance gene; 
 
 
pEGFPRem : Eucaryotic expression vector encoding EGFP-tagged MMTV 
Rem fusion protein. 
 
 
P CMV : promoter of human Cytomegalovirus; eGFPRem : enhanced green fluorescent 
protein fused to MMTV Rem; kan/neo : kanamycin and neomycin resistance gene; 
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pCMVEGFP : Eucaryotic expression vector encoding enhanced green 
fluorescent protein EGFP. 
 
 
CMV : promoter of human Cytomegalovirus; MCS : Multiple Cloning Site; EGFP : enhanced 
green fluorescent protein; Sp6 : Sp6 promoter; poly A : polyadenylation signal; SV40 pr. : 
SV40 early promoter; SV40 ori : SV40 origin of replication; SV40 poly A : SV40 
polyadenylation signal; amp : β-lactamase encoding ampicillin resistance gene; Neo : 
Neomycin resistance gene; 
 
List of plasmids 
 
name origin 
pETRevCHis Müllner Matthias 
pETRemSPCHis Müllner Matthias 
pTZSRS Müllner Matthias 
pTZSRmS Glanz Stephan 
pCMVRev Müllner Matthias 
pCMVRemCHis Müllner Matthias 
p3C-RRE Müllner Matthias 
p3C-RmRE Müllner Mathias 
pCMVSRS Müllner Matthias 
pCMVSRmS Glanz Stephan 
pEGFPRev Indik Stanislav 
pEGFPRem Indik Starnislav 
pCMVEGFP Indik Stanislav 
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8.3 List of primers 
 
PCR performed in results, 5.3.1 : 
“Primer pair A” : 
(forward primer)  
5’ - TAT ATC TAG ACA GTG GGA ATA GGA GCT TTG - 3’  
(reverse primer) 
5’ - AGG AGC TGT TGT CCT TTA GGT ATC - 3’ 
 
PCR performed in results, 5.3.2 : 
“Primer pair B” : 
(forward primer)  
5’ - CGG ATC CGG AGT GAA GGC TTT AAA TC – 3’  
(reverse primer) 
5’ – CAA ATG CGA TCC CTG TGG TCC TTG C – 3’   
 
8.4 List of antibodies 
 
antibody species dilution origin 
α-HIV-1 Rev sheep 1:4500 Fitzgerald 
α-HIV-1 Rev mouse 1:500 NIBSC Unaids 
α-HIV-1 Rev mouse 1:500 NIBSC Unaids 
α-HIV-1 p24 mouse 1:1000 Polymun 
α-MMTV Rem mouse pre-diluted Hochman J. 
α-EGFP mouse 1:1000 Clontech 
α-mouse rabbit 1:10000 DAKO 
α-sheep mouse 1:1300 DAKO 
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8.5 List of cell lines  
HEK293 cells (ATCC CRL-1573) : 
The HEK293 cells are a hypotriploid cell line originating from human 
embryonic kidneys, which was established by transformation with adenovirus 
type 5 (Louis et al., 1997). A subcultivation of 1:10 to 1:20 and a medium 
renewal 2-3 times per week is recommended by ATCC. 
 
CrFK cells (ATCC CCL-94) : 
This cell line is derived from feline kidneys (Crandell et al., 1973). A 
subcultivation of 1:3 to 1:8 and a medium renewal 2-3 times per week is 
recommended by ATCC. 
8.6 Chemicals and Reagents 
 
2-Mercaptoethanol Sigma-Aldrich 
Acetic acid  Merck 
Acetone  Merck 
Acrylamide 29:1 Bio-Rad 
Agarose  Invitrogen 
Agar, bacterial grade Difco 
Ammonium persulfate AppliChem 
Ampicillin  Sigma-Aldrich 
Aqua bidestillata Mayerhofer 
Bovine serum albumin (BSA) Promega 
Bromphenol blue Sigma-Aldrich 
Deoxyribonucleotide triphosphates (dNTPs) Promega 
Diethyl pyrocarbonate (DEPC) Sigma  
Dimethyl sulfoxide (DMSO) Fluka 
Dithiothreitol (DTT) Sigma-Aldrich 
Dulbecco’s modified Eagle’s medium (DMEM) Invitrogen 
Ethanol  Sigma-Aldrich 
Ethylene-diamine-tetraacetate  (EDTA) Sigma-Aldrich  
Ethidium bromide Sigma-Aldrich 
Foetal calf serum Invitrogen 
Formaldehyde Sigma-Aldrich 
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Glycerine  Sigma-Aldrich 
Glycine  Sigma-Aldrich 
IGEPAL  Sigma-Aldrich 
Isopropyl β-D-1-thiogalactopyranoside (IPTG) Serva 
Imidazole  Merck 
Isopropanol  Sigma-Aldrich 
Lipofectamine 2000 Invitrogen 
Magnesium chloride Sigma-Aldrich  
Methanol  Sigma-Aldrich 
3-(N-morpholino)propanesulfonic acid (MOPS) Inotech 
Phenylmethanesulfonylfluoride (PMSF) AppliChem 
Phosphate buffered saline (PBS) AppliChem 
Potassium chloride Sigma-Aldrich 
Protease inhibitor cocktail Sigma-Aldrich 
RNA loading dye (2x) Fermentas 
Select peptone 140 AppliChem 
Sepharose 6B GE Healthcare 
Sodium acetate Sigma-Aldrich 
Sodium chloride Merck 
Sodium dodecyl sulfate Sigma-Aldrich 
Sodium hydroxide Merck 
Sodium hydrogen carbonate Merck 
Sodium phosphate Merck 
Streptomycin Sigma-Aldrich 
Dihydrostreptomycin Sigma-Aldrich 
Orange G  Merck 
Tetramethylethylenediamine (TEMED) Bio-Rad 
Tris  AppliChem 
Tris-base  AppliChem 
Triton X-100  Merck 
0.05% Trypsin-EDTA Invitrogen 
Tween 20  Bio-Rad 
Xylene cyanol Merck 
Yeast extract AppliChem 
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8.7 Curriculum vitae 
 
 
 
Personal information  
Surname / First name Glanz Stephan 
Address Nordmanngasse 23/1/9, 1210 Vienna , Austria 
Telephone (+43)/699 11 78 80 74 
E-mail stephan.glanz@chello.at 
Nationality Austrian 
Date of birth 10 Feb.1984 
Mother tongue German 
Other languages English : excellent 
French : basics 
Italian : basics 
  
Education  
 Since January 2009 Diploma thesis 
 Institute of Virology at the Veterinary University of Vienna 
Since September 2004 
 
Magister study of Gene- and Biotechnology (equivalent Master of Science) 
Examination fields : molecular pathology and biotechnology. 
  University of Vienna, Vienna Biocenter, Max F. Perutz Laboratories, IMBA 
  
Research experience  
August 2008-December 2008 Internship, Institute of Virology, establishment of a novel approach for the isolation of viral 
RNA binding proteins in vivo. 
 Institute of Virology at the Veterinary University of Vienna 
  
Presentations  
 September 2010 Stephan Glanz , Matthias Müllner, John Dangerfield, Walter H. Günzburg, Stanislav Indik, 
Christine Hohenadl. The StreptoTag method in vivo – proof of principle. ÖGMBT Meeting 
2010, Vienna (Poster presentation) 
September 2009 Stephan Glanz , Matthias Müllner, John Dangerfield, Walter H. Günzburg, Stanislav Indik, 
Christine Hohenadl. Affinity chromatography-based isolation of RNA binding proteins in 
physiological conditions. ÖGMBT Meeting 2009, Innsbruck (Poster presentation) 
June 2009 Stephan Glanz , Matthias Müllner, John Dangerfield, Walter H. Günzburg , Stanislav Indik, 
Christine Hohenadl. The in vivo StreptoTag method: a new technique for isolation of RNA 
binding proteins. FEBS Meeting 2009, Prague (Poster presentation) 
  
Skills and competences  
 - Autonomy : During my diploma work I was independently preparing progress reports and 
Journal Clubs. Practical obstacles were presented and discussed in Lab meetings. I took 
the opportunity to present my data several times at scientific meetings.  
 
- Team work : I appreciated to work in an international and interdisciplinary team which 
helped me to target and overcome the many obstacles I encountered in all day research 
life. The input of scientists from multiple disciplines I made contact with on congresses 
provided me with different viewing angles helping me to overcome practical challenges. 
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Other work experiences  
February 2006 onwards Quality Control & Documentation 
 Glanz Electrics 
  
March 2005 onwards Co-Founder of sailing club to promote offshore sailing 
 Sailing4fun 
  
 July 2004 onwards Skipper and organizer of offshore regattas with numerous top rankings in international events  
 Round Palagruza Cannonbal 2007-10, BMW Hochseemeisterschaften, Jabuka Race,. 
  
Summer 2004 Truck Catering VIA 
 Vienna International Airport 
  
September 2003 - May 2004 Military Service: Truck driver; Border Protection at Kittsee 
 Austrian Military 
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